

***United States Cancer Statistics***  
**Restricted Access Data Set**

**Data Dictionary and Data Standards**  
**2016 November Data Submission**

**Centers for Disease Control and Prevention**  
**National Center for Chronic Disease Prevention & Health Promotion**  
**Division of Cancer Prevention and Control**  
**Cancer Surveillance Branch**

**National Cancer Institute**  
**Division of Cancer Control and Population Sciences**  
**Surveillance Research Program**

**June 2017**

## Overview

The National Program of Cancer Registries (NPCR), administered by the Centers for Disease Control and Prevention (CDC), was established by Congress in 1992. Through cooperative agreements, NPCR supports central cancer registries in 45 states, the District of Columbia, Puerto Rico, and the U.S. Pacific Island Jurisdictions. Every year since 2000, the NPCR central cancer registries have been submitting relevant demographic and clinical information about each diagnosed cancer case to CDC.

CDC works closely with a variety of partners to deliver and manage this cancer surveillance system. One of CDC's most critical partners is the National Cancer Institute (NCI), which funds the Surveillance, Epidemiology, and End Results (SEER) Program. Together, CDC's NPCR and NCI's SEER programs cover the entire United States population.

The programs' combined data are referred to as the United States Cancer Statistics (USCS) and they are the official source of federal statistics on cancer incidence. USCS data are available to the public through the [United States Cancer Statistics \(USCS\) Incidence and Mortality Web-based Report](#); external researchers have additional access to USCS through the **USCS Restricted Access Data Set**.

### Available Data

This file documents the data items included in the **USCS Restricted Access Data Set, 1998-2014**.

The purpose of this document is to define data standards for data items included in the *United States Cancer Statistics* (USCS) Restricted Access Dataset (RADs) of the CDC's National Program of Cancer Registries (NPCR) Cancer Surveillance System (CSS) and NCI's Surveillance, Epidemiology, and End Results (SEER) Program. These variables are routinely collected through NPCR and SEER, and are defined by the North American Association of Central Cancer Registries (NAACCR). The following document describes the data items.

For all variables defined by NAACCR standards, abstractors use NAACCR's *Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary*, in use for the given diagnosis year.

The data come from the 2016 NPCR-Cancer Surveillance System (NPCR-CSS) and SEER submissions.

- NPCR allowed an interval of 23 months after the close of the diagnosis year (data submission by November 30, 2016), and

- SEER allowed an interval of 22 months after the close of the diagnosis year (data submission by November 1, 2016).

For the percent population coverage by year, please see the Excel file “uscs\_eligible\_povcov\_9814\_Nov2016sub.” The percent of cases covered by USCS-eligible registries is as follows:

- 1998-2014: ~89.4%
- 1999-2014: ~96.8%
- 2005-2014: ~99.1%
- 2010-2014: ~99.1%.

In fall 2005, hurricanes Katrina and Rita hit the gulf coast and caused dramatic population shifts in the region. The US Census Bureau has provided estimates of the displaced populations within the four states of Alabama, Louisiana, Mississippi, and Texas. The adjusted US Census population estimates should be used; county-level populations in the four hurricane-affected states should be adjusted to account for evacuations and that portion of the population be put into a “dummy” state (otherwise known as the KR area) for 2005.

## Cautionary Notes

Before using the database, analysts should read and understand the following nuances of the data set.

### State Inclusion

- Note that data from all registries are not represented each year. Data from each registry must meet eligibility criteria for publication in the *United States Cancer Statistics* (USCS) to be included in this dataset and a state may be included for some years but not for all. States are also given the right to opt out of including their data in the dataset. Examine the table of state by year of diagnosis prior to beginning your analysis. See the Excel file referenced above. See the USCS Eligibility Criteria section for more information on the criteria.
- Four user-specified variables are included in the database: uscs9814, uscs9914, uscs0514, and uscs1014, for analyses using grouped years of data. These are particularly important for trend analyses, where the same states need to be included for each year under investigation. These user-specified variables contain all registries meeting USCS criteria for all years included in the name of each variable (for example, uscs1014 includes states that have data available for all five years, 2010 through 2014). Additionally, the USCS standard variable, USCS standard, is to be used for single year analyses.

## Suppression Rules

- The suppression rule is <16 cases for the time period based on rate stability. When the numbers of cases used to compute the incidence rates are small, those rates tend to have poor reliability. Therefore, to discourage misinterpretation and misuse of counts, rates, and trends that are unstable because of the small number of cases or deaths, these statistics are not shown in tables and figures if the counts are less than 16 for the time period. A count of less than approximately 16 in a numerator results in a standard error of the rate that is approximately 25% or more as large as the rate itself. Equivalently, a count of less than approximately 16 results in the width of the 95% confidence interval around the rate being at least as large as the rate itself. These relationships were derived under the assumption of a Poisson process and with the standard population age distribution close to the observed population age distribution.
- Another important reason for employing a cell suppression threshold value is to protect the confidentiality of patients whose data are included in a report by reducing or eliminating the risk of identity disclosure. The cell suppression threshold value of 16 is recommended to protect patient confidentiality given the low level of geographic and clinical detail provided. More information can be found at:
  1. Federal Committee on Statistical Methodology. Report on Statistical Disclosure Limitations Methodology (Statistical Working Paper 22). Washington, DC: Office of Management and Budget; 2005. Available at <http://www.fcsm.gov/working-papers/spwp22.html>
  2. Doyle P, Lane JI, Theeuwes JM, Zayatz LM. Confidentiality, Disclosure, and Data Access: Theory and Practical Applications for Statistical Agencies. Amsterdam: Elsevier Science; 2001.

## Reporting Delay

- Note that data are resubmitted by each NPCR and SEER registry each year. New cases are added each year to previous years resulting in a reporting delay. Cases may also be deleted from older years. Cases for certain primary sites e.g., melanoma and prostate, that are diagnosed on an out-patient basis can appear to be dropping in the most recent year. Further discussion can be found in Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. *Journal of the National Cancer Institute* 2002;94(20):1537-45 (<http://www.ncbi.nlm.nih.gov/pubmed/?term=12381706>).

## Race and Ethnicity

### *Data Suppression*

- States have the option to suppress race-specific and Hispanic ethnicity-specific data every submission year. While these states can be included in an aggregated analysis, the affected state's race and ethnicity information cannot be reported at the state level.

- The variable, “Stateraceethincl”, can be used to restrict your analysis to the states that are eligible to be included in a state- or county-level analysis of race and ethnicity.
- If “Stateraceethincl” is not used and state- or county-level data are being reported, the following suppressions must be made when using data from the 2016 submission:
  - Hispanic ethnicity data cannot be displayed for Arkansas, Delaware, Kentucky, and Massachusetts.
  - Data for American Indians and Alaska Natives (AI/AN) cannot be displayed for Delaware, Illinois, Kentucky, New Jersey, and New York.
  - Data for Asian and Pacific Islanders (API) cannot be displayed for Arkansas, Delaware, and Kentucky.
  - Race and ethnicity combinations—white Hispanic, white non-Hispanic, black Hispanic, black non-Hispanic— cannot be displayed for Arkansas, Delaware, Kentucky, Massachusetts and Pennsylvania.

#### *Race Recode variable*

- This variable is created from Race1, Race2, and the Indian Health Service Link variable. Race/ethnicity starts as Race1. If Race1 is white and Race 2 is a specified non-white race, then the value from Race2 is used. After this check, if Race/ethnicity is still white and there is a positive IHS Link, then Race/Ethnicity is set to American Indian/Alaskan Native.
- The “race recode” variable contains an “other unspecified category”. This group is treated as unknown race for the purpose of analyses as per the [SEER documentation](#). Population data are not available for the other and unknown race categories.

#### *Indian Health Service-linked American Indian/Alaska Natives (AI/AN) data*

- IHS provides medical services to AI/ANs who are members of federally recognized tribes, estimated to be about 65% of the AI/AN population. To improve identification of AI/ANs, 31 NPCR registries with Contract Health Service Delivery Area (CHSDA) counties in their state annually link with the IHS patient registration database to identify AI/ANs who had not been coded as AI/AN (see “IHS Link” variable description). All NPCR registries link every five years. Linkages were performed by all NPCR registries most recently in 2011 and 2016 (cases diagnosed 1995-2014). In 2016, SEER registries linked cancer cases diagnosed from 1994-2014.
  - When interpreting data results, be aware that AI/AN populations may be undercounted during years when linkages did not occur in all NPCR registries.
  - If a project is looking specifically at AI/AN populations, analysts may consider restricting the analysis to registries that conduct annual IHS linkages.

- The “race recode” variable contains Indian Health Service (IHS)-linked American Indian data.

### **Sex**

- When analyzing sex-specific cancers (such as prostate cancer or female breast cancer), the analysis should be limited to the appropriate sex to get the correct population denominator (e.g. only women or only men).

### **County**

- County data may be used only in approved analyses and in the following ways: a) used as a linkage variable only by the NCHS RDC analyst; b) included as a confounder or other control variable, but no data are presented by county; c) used in geographically aggregated form such as large metropolitan statistical areas (e.g., those with a population of 1 million or later), multi-county regions, or geographical areas (e.g., Appalachia or IHS Contract health Services Delivery Areas (CHSDA) counties). States are given the right to suppress county-specific data every submission year.

### **Stage**

- Stage at diagnosis, or the extent to which the cancer has spread at the time it was originally diagnosed, is recorded using SEER Summary Stage 1977 through diagnosis year 2000, Summary Stage 2000 for diagnosis years 2001-2003, and the Collaborative Stage Data Collection System to derive Summary Stage 2000 for diagnosis years 2004-2011. As a general rule, Derived Summary Stage 2000 data should be analyzed for diagnosis years 2004-2014 in this file. Summary Stage 2000 should be used with 2001-2003 cases, and Summary Stage 1977 should be used with earlier cases.

In certain circumstances when information is not available to calculate the Derived Summary Stage 2000, NPCR permits the use of Summary Stage 2000 for diagnosis years 2004-2014. As a result, when stage information is required, it is recommended that the “Merged Summary Stage 2000” variables described below be used to account for missing information in Derived Summary Stage 2000.

When the coding instructions between the three systems do not vary appreciably for a given primary site, a merged variable can be created and used for Summary Stage cases across 1998-2014. For primary sites where the coding instructions changed to redistribute the percentage of cases coded as localized, regional, and distant, analyses should be limited to 2001 cases and forward. See the NAACCR “Site-Specific Comparison of Summary Stage 1977 and Summary Stage 2000 Coding” for specific information.

- A merged variable, “Merged Summary Stage 2000,” has been created to span two time periods when two different staging schemes were used. Stage at diagnosis is recorded

using “SEER Summary Stage 2000” for diagnosis years 2001-2003 and “Derived SEER Summary Stage 2000” for diagnosis years 2004-2014.

The coding logic for this merged variable is:

- If a case was diagnosed between 2001 and 2003, stage at diagnosis is recorded using the “SEER Summary Stage 2000” variable value.
- If a case was diagnosed between 2004 and 2013, then the stage at diagnosis is recorded using the “Derived SEER Summary Stage 2000” variable value.
- If the “Derived SEER Summary Stage 2000” variable is blank and a valid value is available for the “SEER Summary Stage 2000” variable, that value is used to populate the merged variable. For example, if a case was diagnosed in 2013 and “Derived SEER Summary Stage” was blank, but “SEER Summary Stage” had a value of “local,” then the merged variable was coded as local stage. Otherwise, the merged variable is left blank for that record.

### **Primary Site Variables**

- Beginning in diagnosis year 2010, some of the lymphoma and leukemia ICD-O-3 codes were updated based on changes from the World Health Organization. These changes are incorporated into the site recode variables in this data set.
- If the standard primary site recode variable is not used and a user-defined primary site variable is created, leukemias and lymphomas (9590-9989) should be excluded. Users may also want to break out Kaposi sarcoma (9140) and mesothelioma (9050-9055). For more information on the SEER primary site recode, see <http://seer.cancer.gov/siterecode/>.

### **Benign Central Nervous System (CNS) Tumors**

- Cancer registries began collecting information on nonmalignant brain and other nervous system tumors beginning with 2004 diagnoses. Collection of these tumors is in accordance with Public Law 107–260, the Benign Brain Tumor Cancer Registries Amendment Act, which mandates that NPCR registries collect data on all brain and other nervous system tumors with a behavior code of 0 (benign) and those with a behavior code of 1 (borderline), in addition to *in situ* and malignant. SEER registries voluntarily agreed to incorporate registration of these tumors in their standard practices. Data for nonmalignant brain and other nervous system tumors were available from all registries contributing to this report.

### **Histology**

- For analyses that include histology, “diagnostic confirmation=microscopically confirmed” should be selected since this selection also automatically excludes the death certificate only (DCO) cases.

## Behavior

- ICD-O-2 behavior coding was used for cases diagnosed between 1992 and 2000 (1998-2000 in this data set). Cases diagnosed January 1, 2001 and after use the ICD-O-3 classification system. ICD-O-2 cases were converted to ICD-O-3 before they were submitted for this data set.
- If the analysis only includes cases diagnosed in 2001 or later, use the variable “Behavior code ICD-O-3”.
- If the analysis includes cases diagnosed in 1998, 1999, and/or 2000, and also spans diagnosis years  $\geq 2001$ , then use “Behavior recode for analysis”. This variable reconciles the differences between ICD-O-2 and ICD-O-3. The ICD-O-3 manual, Appendix 6, has a complete list of behavior code changes.

## Data Citation

The following standard citations are to be used for all tables and figures when presented in presentations or publications.

- **For population coverage:** Data are from population-based registries that participate in the National Program of Cancer Registries or Surveillance, Epidemiology, and End Results Program and meet high-quality data criteria. These registries cover approximately [XX]% of the U.S. population.
- **For age-adjusted rates:** Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130).

## USCS Eligibility Criteria

After years of analyzing completeness of case ascertainment, we have determined that our registries consistently deliver high quality, complete data. We have discontinued using completeness of case ascertainment calculations as a measure of eligibility for publication. The data quality criteria—missing/unknown data, death certificate only percentage, duplicate rate, and percent records passing edits—will continue to be used in determining inclusion. Even though the completeness estimate will no longer be a criterion for USCS, we will continue to use this estimate to monitor and evaluate progress in meeting NPCR Program Standards.

Cancer registries in the “meets uscs criteria” category for each year and for groups of years at the Regional Level meet the following data quality criteria for all cancer sites combined:



- *No more than 5% of cases are ascertained solely on the basis of a death certificate.* The proportion of cases ascertained solely on the basis of a death certificate, with no other information on the case available after the registry has completed a routine procedure known as “death clearance and followback,”<sup>5-7</sup> is another measure of the completeness of case ascertainment.
- *No more than 3% of cases are missing information on sex.*
- *No more than 3% of cases are missing information on age.*
- *No more than 5% of cases are missing information on race.*
- *At least 97% of the registry’s records passed a set of single-field and interfield computerized edits.* Computerized edits are computer programs that test the validity and logic of data components. For example, if (a) a patient received a diagnosis of cancer in 1999, (b) the patient’s age was reported as 80 years, and (c) the patient’s year of birth was reported as 1942, a computerized edit could, without human intervention, identify these components as incompatible. The computerized edits applied to the data in this report are incorporated into NAACCR standards (<http://www.naacccr.org>) and into the EDITS software designed and maintained by CDC (<http://www.cdc.gov/cancer/npcr/tools/edits/>).

The measurement error for these criteria may vary in select circumstances, following review by CDC and/or NCI.

1. Tucker TC, Howe HL, Weir HK. Certification of population-based cancer registries. *Journal of Registry Management* 1999;26(1):24-7.
2. Tucker TC, Howe HL. Measuring the quality of population-based cancer registries: the NAACCR perspective. *Journal of Registry Management* 2001;28(1):41-4.
3. Ellison JH, Wu X, McLaughlin C, Lake A, Firth R, Cormier M, Leonfellner S, Carozz SE, Roney D, Howe HL, Kosary CL. *Cancer in North America, Volume One: Incidence, 1999-2003*. Springfield, IL: North American Association of Central Cancer Registries; 2006. Available at [http://www.naacccr.org/index.asp?Col\\_SectionKey=11&Col\\_ContentID=50](http://www.naacccr.org/index.asp?Col_SectionKey=11&Col_ContentID=50).
4. Howe HL. *Conclusions of the Workgroup for High-Quality Criteria for Data Use: The NAACCR Narrative*. Springfield, IL: North American Association of Central Cancer Registries; 2001.
5. Havener L. *Standards for Cancer Registries, Volume III: Standards for Completeness, Quality, Analysis, and Management of Data*. Springfield, IL: North American Association of Central Cancer Registries; 2004.

6. Menck HR, Phillips JL. Central cancer registries. In: Hutchinson CL, Menck HR, Burch M, Gottschalk R, editors. *Cancer Registry Management: Principles and Practice*. 2<sup>nd</sup> ed. Dubuque, IA: Kendall/Hunt Publishing Company; 2004.
7. Seiffert JE, Hoyler SS, McKeen K, Potts M. Casefinding, abstracting, and death clearance. In: Menck HR, Smart C, editors. *Central Cancer Registries: Design, Management, and Use*. Chur, Switzerland: Harwood Academic Publishers; 1994.

## Table of Contents

### Section: Demographic Data Items

Alternate Patient ID Number .....	13
Address at Diagnosis – State.....	14
Address at Diagnosis – County.....	15
USCS Standard .....	16
USCS9914.....	17
USCS1014.....	18
USCS9814.....	19
USCS0514.....	20
Address at Diagnosis – Census Region .....	21
Race 1.....	22
Race 2.....	23
Race Recode.....	24
Spanish/Hispanic Origin .....	25
NHIA Derived Hispanic Origin .....	27
IHS Link.....	29
Sex.....	31
Age at Diagnosis .....	32
Age Recode.....	33
Birth Date.....	34

### Section: Cancer Identification Data Items

Sequence Number – Central .....	35
Date of Diagnosis.....	37
Primary Site .....	38
Laterality .....	39
Grade.....	40
Diagnostic Confirmation.....	42
Type of Reporting Source.....	43
Histologic Type ICD-O-3 .....	44
Behavior Code ICD-O-3.....	45
Behavior Recode for Analysis .....	46
Primary Site Recode .....	47
Primary Site Recode with Mesothelioma and Kaposi Sarcoma .....	48
SEER International Classification of Childhood Cancer (ICCC) Recode.....	49

### Section: Stage/Prognostic Factors Data Items

SEER Summary Stage 2000 .....	50
SEER Summary Stage 1977 .....	52
CS Extension.....	54
CS Lymph Nodes .....	55
CS Mets at DX .....	56
CS Site-Specific Factor 1 .....	57

CS Site-Specific Factor 2.....	58
CS Site-Specific Factor 3.....	59
CS Site-Specific Factor 15.....	60
CS Site-Specific Factor 25.....	61
CS Version Input Original .....	62
CS Version Derived .....	63
CS Version Input Current .....	64
Derived SS2000 .....	65
Merged Summary Stage 2000.....	67

Section: Over-ride flags

Over-ride Age/Site/Morph.....	68
Over-ride SeqNo/DxConf .....	70
Over-ride Site/Lat/Sequence Number.....	72
Over-ride Site/Type .....	74
Over-ride Histology .....	76
Over-ride Report Source .....	79
Over-ride Ill-define Site.....	81
Over-ride Leuk, Lymphoma .....	83
Over-ride Site/Behavior .....	85
Over-ride Site/Lat/Morph .....	87

Section: Appendices

Appendix I: Sample SAS Analytic File Statements .....	89
---	----

## Section: Demographic Data Items

### Alternate Patient ID Number

#### Alternate Patient ID Number

SAS Alternate Name	Length	Source of Standard
Random_ID	8	NAACCR Item #20

#### Description:

Unique number assigned to an individual patient by the registry. A new unique number is assigned to each Patient ID Number prior to data release for confidentiality reasons. In combination with state at diagnosis, this should uniquely identify a person.

#### Considerations for Use:

None noted

## Section: Demographic Data Items Address at Diagnosis – State

### Address at Diagnosis – State

SAS Alternate Name	Length	Source of Standard
I80_StateDx	2	NAACCR Item #80

### Description

USPS abbreviation for the state, territory, commonwealth, or U.S. possession for the state/territory in which the patient resides at the time the reportable tumor is diagnosed. If the patient has multiple primaries, the state of residence may be different for each tumor.

### Codes (in addition to USPS abbreviations)

CD	Resident of Canada, NOS (province/territory unknown)
US	Resident of United States, NOS (state/commonwealth/territory/possession unknown)
XX	Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is known
YY	Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is unknown
ZZ	Residence unknown

### Considerations for Use:

The following states/diagnosis years are excluded from this file:

Diagnostic Year(s)	Exclusion state(s)
1998	Kansas, Mississippi, Missouri, South Dakota, Tennessee, Puerto Rico
1999	Arkansas, Kansas, Mississippi, Missouri, South Dakota, Puerto Rico
2000	Arkansas, Kansas, Mississippi, Missouri, South Dakota, Puerto Rico
2001	Kansas, Mississippi, Missouri, Puerto Rico
2002	District of Columbia, Kansas, Mississippi, Missouri, Puerto Rico
2003	Kansas, Missouri, Puerto Rico
2004	Kansas, Missouri, Puerto Rico
2005	Kansas, Missouri, Puerto Rico
2006	Kansas, Missouri, Puerto Rico
2007	Kansas, Missouri, Puerto Rico
2008	Kansas, Missouri, Puerto Rico
2009	Kansas, Missouri, Puerto Rico
2010	Kansas, Missouri, Puerto Rico
2011	Kansas, Missouri, Nevada, Puerto Rico
2012	Kansas, Missouri, Puerto Rico
2013	Kansas, Missouri, Puerto Rico
2014	Kansas, Missouri, Puerto Rico

## Section: Demographic Data Items Address at Diagnosis – County

### Address at Diagnosis – County

SAS Alternate Name	Length	Source of Standard
I90_CountyDx	3	NAACCR Item #90

#### Description

Code for the county of the patient’s residence at the time the tumor was diagnosed. For U.S. residents, standard codes are those of the FIPS publication “Counties and Equivalent Entities of the United States, Its Possessions, and Associated Areas.” If the patient has multiple tumors, the county codes may be different for each tumor.

*Note:* See Appendix A for standard FIPS county codes.

#### Codes (in addition to FIPS and Geocodes)

000 United States, Not Otherwise Specified  
999 County unknown

#### Considerations for Use:

County data will be used only in approved analyses and in the following ways: a) used as a linkage variable (linkage to census data, for example) only by the NCHS RDC analyst; b) included as a confounder or other control variable, but no data are presented by county; c) used in geographically aggregated form such as large metropolitan statistical areas (e.g., those with a population of 1 million or larger), multi-county regions, or geographical areas (e.g., Appalachia or IHS Contract Health Services Delivery Areas (CHSDA) counties).

The following states did not allow permission for their county data to be used: Illinois, Michigan, and Minnesota. The County at Diagnosis variable for these states has been recoded to 000 for all diagnosis years.

## Section: Demographic Data Items USCS Standard

### USCS Standard

SAS Alternate Name	Length	Source of Standard
USCSSTD	1	NPCR

### Description

This variable indicates the NPCR-funded central cancer registries with cancer incidence data that are of high quality and meet the USCS standard for a single year of analysis at the national level for all cancer sites combined.

### Considerations for use

- This variable allows the selection of only those central cancer registries whose data meet the USCS standard for an individual diagnosis year.
- If you are conducting a multiyear analysis and want to restrict the analysis to the states that met publication criteria for each of those years (for example, a trend analysis), we recommend using the predefined variables, USCS1014 (includes diagnosis years 2010–2014), USCS0514 (includes diagnosis years 2005–2014), USCS9914 (includes diagnosis years 1999–2014) or USCS9814 (includes diagnosis years 1998–2014).
- The USCS publication standard is available at [https://www.cdc.gov/cancer/npcr/uscs/technical\\_notes/criteria.htm](https://www.cdc.gov/cancer/npcr/uscs/technical_notes/criteria.htm).



## Section: Demographic Data Items USCS9914

### USCS9914

SAS Alternate Name	Length	Source of Standard
USCS9914	1	NPCR

### Description

This variable indicates whether NPCR-funded central cancer registries met the USCS publication standard for all cancer sites combined each year in 1999–2014. When using this variable, restrict the diagnosis years to 1999–2014.

### Considerations for use

- This variable is used for analysis of combined 1999–2014 data in the 1998–2014 database. Data from states that did not meet the USCS publication standard in any given year were excluded from the database for that year. Please refer to the population coverage Excel file for the list of states by year that were included and excluded by this variable.
- If you are conducting a multiyear analysis and want to restrict the analysis to the states that met publication criteria for each of those years (for example, a trend analysis), we recommend using the predefined variables, USCS1014 (includes diagnosis years 2010–2014), USCS0514 (includes diagnosis years 2005–2014), USCS9914 (includes diagnosis years 1999–2014) or USCS9814 (includes diagnosis years 1998–2014).
- The USCS publication standard is available at [https://www.cdc.gov/cancer/npcr/uscs/technical\\_notes/criteria.htm](https://www.cdc.gov/cancer/npcr/uscs/technical_notes/criteria.htm).

## Section: Demographic Data Items USCS1014

### USCS1014

SAS Alternate Name	Length	Source of Standard
USCS1014	1	NPCR

### Description

This variable indicates whether NPCR-funded central cancer registries met the USCS publication standard for all cancer sites combined each year in 2010–2014 (the most recently submitted 5 years of data). When using this variable, restrict the diagnosis years to 2010–2014.

### Considerations for use

- This variable is used for analysis of combined 2010–2014 data in the 1998–2014 database. Data from states that did not meet the USCS publication standard in any given year were excluded from the database for that year. Please refer to the population coverage Excel file for the list of states by year that were included and excluded by this variable.
- If you are conducting a multiyear analysis and want to restrict the analysis to the states that met publication criteria for each of those years (for example, a trend analysis), we recommend using the predefined variables, USCS1014 (includes diagnosis years 2010–2014), USCS0514 (includes diagnosis years 2005–2014), USCS9914 (includes diagnosis years 1999–2014) or USCS9814 (includes diagnosis years 1998–2014).
- The USCS publication standard is available at [https://www.cdc.gov/cancer/npcr/uscs/technical\\_notes/criteria.htm](https://www.cdc.gov/cancer/npcr/uscs/technical_notes/criteria.htm).

## Section: Demographic Data Items USCS9814

### USCS9814

SAS Alternate Name	Length	Source of Standard
USCS9814	1	NPCR

### Description

This variable indicates whether NPCR-funded central cancer registries met the USCS publication standard for all cancer sites combined each year in 1998–2014. When using this variable, restrict the diagnosis years to 1998–2014.

### Considerations for use

- This variable is used for analysis of combined 1998–2014 data in the 1998–2014 database. Data from states that did not meet the USCS publication standard in any given year were excluded from the database for that year. Please refer to the population coverage Excel file for the list of states by year that were included and excluded by this variable.
- If you are conducting a multiyear analysis and want to restrict the analysis to the states that met publication criteria for each of those years (for example, a trend analysis), we recommend using the predefined variables, USCS1014 (includes diagnosis years 2010–2014), USCS0514 (includes diagnosis years 2005–2014), USCS9914 (includes diagnosis years 1999–2014) or USCS9814 (includes diagnosis years 1998–2014).
- The USCS publication standard is available at [https://www.cdc.gov/cancer/npcr/uscs/technical\\_notes/criteria.htm](https://www.cdc.gov/cancer/npcr/uscs/technical_notes/criteria.htm).

## Section: Demographic Data Items USCS0514

### USCS0514

SAS Alternate Name	Length	Source of Standard
USCS0514	1	NPCR

### Description

This variable indicates whether NPCR-funded central cancer registries met the USCS publication standard for all cancer sites combined each year in 2005–2014 (the most recently submitted 10 years of data). When using this variable, restrict the diagnosis years to 2005–2014.

### Considerations for use

- This variable is used for analysis of combined 2005–2014 data in the 1998–2014 database. Data from states that did not meet the USCS publication standard in any given year were excluded from the database for that year. Please refer to the population coverage Excel file for the list of states by year that were included and excluded by this variable.
- If you are conducting a multiyear analysis and want to restrict the analysis to the states that met publication criteria for each of those years (for example, a trend analysis), we recommend using the predefined variables, USCS1014 (includes diagnosis years 2010–2014), USCS0514 (includes diagnosis years 2005–2014), USCS9914 (includes diagnosis years 1999–2014) or USCS9814 (includes diagnosis years 1998–2014).
- The USCS publication standard is available at [https://www.cdc.gov/cancer/npcr/uscs/technical\\_notes/criteria.htm](https://www.cdc.gov/cancer/npcr/uscs/technical_notes/criteria.htm).

## Section: Demographic Data Items Address at Diagnosis – Census Region

### Address at Diagnosis – Census Region

SAS Alternate Name	Length	Source of Standard
CENSUS_REGION	9	Derived based upon NAACCR Item #80

#### Description

The region where the patient lived at diagnosis.

#### Codes

The NAACCR data item Address at Diagnosis—State [80] is recoded into one of the four Census regions, the same definition used for region in United States Cancer Statistics. Reference [http://www.census.gov/geo/www/us\\_regdiv.pdf](http://www.census.gov/geo/www/us_regdiv.pdf) for a list of states for each region. US Census Regions are Northeast, Midwest, South, and West.

#### Considerations for Use:

Do not confuse this variable with census tract. Census tract data are not included in this dataset.

## Section: Demographic Data Items

### Race 1

#### Race 1

SAS Alternate Name	Length	Source of Standard
I160_Race1	2	NAACCR Item #160

#### Description

Code for the patient's race. Race is coded separately from Spanish/Hispanic Origin [190]. All tumors for the same patient should have the same race codes. If the patient is multiracial, a second race is coded in the data item RACE 2 [161]. For coding instructions and race code history see the current *SEER Program Coding and Staging Manual*. Reference to Census 2000 definitions for ethnicity and race: <http://www.census.gov/prod/cen2000/doc/sf2.pdf>

#### Rationale

Because race has a significant association with cancer rates and outcomes, a comparison between areas with different racial distributions may require an analysis of race to interpret the findings. The race codes listed correspond closely to race categories used by the U.S. Census Bureau to allow calculation of race-specific incidence rates. The full coding system should be used to allow accurate national comparison and collaboration, even if the state population does not include many of the race categories.

#### Codes

01 White	12 Hmong	26 Tahitian
02 Black	13 Kampuchean (Cambodian)	27 Samoan
03 American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere)	14 Thai	28 Tongan
04 Chinese	15 Asian Indian or Pakistani, NOS (code 09 prior to Version 12)	30 Melanesian, NOS
05 Japanese	16 Asian Indian	31 Fiji Islander
06 Filipino	17 Pakistani	32 New Guinean
07 Hawaiian	20 Micronesian, NOS	96 Other Asian, including Asian, NOS and Oriental, NOS
08 Korean	21 Chamorro/Chamoru	97 Pacific Islander, NOS
10 Vietnamese	22 Guamanian, NOS	98 Other
11 Laotian	25 Polynesian, NOS	99 Unknown

#### Considerations for Use:

Population data are not available for this variable. For age-adjusted rates by race, "NPCR Race Recode" should be used. This variable is used to derive the "NPCR Race Recode".

When analyzing data at the state level, AIAN data cannot be broken out for Delaware, Illinois, Kentucky, New Jersey, and New York. API data cannot be broken out for Delaware and Kentucky. States are given the right to suppress race-specific data every submission year.

## Section: Demographic Data Items

### Race 2

#### Race 2

SAS Alternate Name	Length	Source of Standard
I161_Race2	2	NAACCR Item #161

#### Description

Code for the patient's race. Race is coded separately from Spanish/Hispanic Origin [190]. All tumors for the same patient should have the same race codes. If the patient is multiracial, the second race is coded in this data item. For coding instructions and race code history see the current *SEER Program Coding and Staging Manual*. Reference to Census 2000 definitions for ethnicity and race:

<http://www.census.gov/prod/cen2000/doc/sf2.pdf>

#### Rationale

Because race has a significant association with cancer rates and outcomes, a comparison between areas with different racial distributions may require an analysis of race to interpret the findings. The race codes listed correspond closely to race categories used by the U.S. Census Bureau to allow calculation of race-specific incidence rates. The full coding system should be used to allow accurate national comparison and collaboration, even if the state population does not include many of the race categories.

#### Codes

01 White	12 Hmong	26 Tahitian
02 Black	13 Kampuchean (Cambodian)	27 Samoan
03 American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere)	14 Thai	28 Tongan
04 Chinese	15 Asian Indian or Pakistani, NOS (code 09 prior to Version 12)	30 Melanesian, NOS
05 Japanese	16 Asian Indian	31 Fiji Islander
06 Filipino	17 Pakistani	32 New Guinean
07 Hawaiian	20 Micronesian, NOS	96 Other Asian, including Asian, NOS and Oriental, NOS
08 Korean	21 Chamorro/Chamoru	97 Pacific Islander, NOS
10 Vietnamese	22 Guamanian, NOS	98 Other
11 Laotian	25 Polynesian, NOS	99 Unknown

#### Considerations for Use:

Population data are not available for this variable. For age-adjusted rates by race, "NPCR Race Recode" should be used. This variable is used to derive the "NPCR Race Recode".

When analyzing data at the state level, AIAN data cannot be broken out for Delaware, Illinois, Kentucky, New Jersey, and New York. API data cannot be broken out for Delaware and Kentucky. States are given the right to suppress race-specific data every submission year.

## Section: Demographic Data Items

### Race Recode

#### Race Recode

SAS Alternate Name	Length	Source of Standard
Race_Recode_For_USCS	8	Derived based upon NAACCR Items #160, #161, and #192

#### Description

The variable contains Indian Health Service-linked American Indian data. For this dataset, all NPCR cancer registries linked cancer cases diagnosed from 1995–2014 with the IHS patient registration database to identify American Indians/Alaska Natives that were classified in the registry as non-native. IHS provides medical services to American Indians/Alaska Natives who are members of federally recognized tribes, estimated to be approximately 65% of the American Indian/Alaska Native population. This variable is created from Race1, Race2, and the Indian Health Service (IHS) Link variable. Race/ethnicity starts as Race1. If Race1 is white and Race 2 is a specified non-white race, then the value from Race2 is used. After this check, if Race/ethnicity is still white and there is a positive IHS Link, then Race/Ethnicity is set to American Indian/Alaskan Native.

The “race recode” variable also contains an “other unspecified category”. This group is treated as unknown race for the purpose of analyses as per the SEER documentation. Population data are not available for the other and unknown race categories.

For further information on creating this variable, see the SAS statements in Appendix I.

#### Codes

This variable combines race into the following categories:

- White
- Black
- American Indian/Alaska Native
- Asian/Pacific Islander
- Other
- Unknown



## Section: Demographic Data Items

### Spanish/Hispanic Origin

#### Spanish/Hispanic Origin

SAS Alternate Name	Length	Source of Standard
I190_SpanishOrigin	1	NAACCR Item #190

#### Description

Code identifying persons of Spanish or Hispanic origin. This code is used by hospital and central registries to show the “best guess” as to whether or not the person should be classified as Hispanic for purposes of calculating cancer rates. If the patient has multiple tumors, all records should have the same code.

Reference to Census 2000 definitions for ethnicity and race:

<http://www.census.gov/prod/cen2000/doc/sf2.pdf>

All information resources should be used to determine the correct code, including:

- Stated ethnicity in the medical record
- Stated Hispanic origin on the death certificate
- Birthplace
- Information about life history and/or language spoken found during the abstracting process
- Patient’s last name [2230] or maiden name [2390] found on a list of Hispanic names

Some registries code the information from the medical record, others code ethnicity based on Spanish names, and others use a combination of methods.

Persons of Spanish or Hispanic origin may be of any race, but these categories generally are not used for Native Americans, Filipinos, etc., who may have Spanish names. If a patient has a Hispanic name, but there is reason to believe they are not Hispanic (e.g., the patient is Filipino, or the patient is a woman known to be non-Hispanic who has a Hispanic married name), the code in this field should be 0 (non-Spanish, non-Hispanic).

Code 7 is assigned if Hispanic ethnicity is based strictly on a computer list or algorithm (unless contrary evidence is available).

*Note:* NAACCR recognizes that available definitions and abstracting instructions for Name--Last [2230] and Name--Maiden [2390] may be inadequate for describing names used in some cultures, including Hispanic cultures. Explicit instructions have not been provided for entering compound names, with or without hyphens or “De.” Order of names, use of maternal and paternal names, and use of hyphens can vary across cultures. It is likely that abstracting and coding practice for these items varies across registries. Limitations inherent in these definitions should be kept in mind when using the data.

#### Rationale

Ethnic origin has a significant association with cancer rates and outcomes. Hispanic populations have different patterns of occurrence of cancer from other populations that may be included in the “white” category of Race [160].

#### Codes

- 0 Non-Spanish; non-Hispanic

- 1 Mexican (includes Chicano)
- 2 Puerto Rican
- 3 Cuban
- 4 South or Central American (except Brazil)
- 5 Other specified Spanish/Hispanic origin (includes European; excludes Dominican Republic)
- 6 Spanish, NOS  
Hispanic, NOS  
Latino, NOS  
There is evidence, other than surname or maiden name, that the person is Hispanic, but he/she cannot be assigned to any of the other categories 1-5.
- 7 Spanish surname only ((Code 7 is ordinarily for central registry use only, hospital registrars may use code 7 if using a list of Hispanic surnames provided by their central registry; otherwise, code 9 “unknown whether Spanish or not” should be used.)  
The only evidence of the person’s Hispanic origin is the surname or maiden name and there is no contrary evidence that the person is not Hispanic.
- 8 Dominican Republic
- 9 Unknown whether Spanish or not

*Note:* Code 7 was adopted for use effective with 1994 diagnosis and modified December 1994.

*Note:* Code 8 was added in Standards Volume II Version 10.2, effective January 2005, however, abstractors may assign code 8 to tumors diagnosed prior to 2005.

**Considerations for Use:**

Due to concerns about under-reporting of Hispanics, the NHIA variable [191] was created to identify Hispanics in 2004. Population data are not available for this variable. For age-adjusted rates by ethnicity, the user-specified variable “Origin recode NHIA (Hispanic/Non-Hispanic)” should be used.

When analyzing data at the state level, Hispanic ethnicity cannot be broken out for Delaware, Kentucky, and Massachusetts. Race and ethnicity combinations—white Hispanic, white non-Hispanic, black Hispanic, and black non-Hispanic—cannot be broken out for Arkansas, Delaware, Kentucky, Massachusetts, and Pennsylvania. States are given the right to suppress ethnicity-specific data every submission year.

## Section: Demographic Data Items

### NHIA Derived Hispanic Origin

#### NHIA Derived Hispanic Origin

SAS Alternate Name	Length	Source of Standard
I191_NHIA	1	NAACCR Item #191

#### Description

The NAACCR Hispanic Identification Algorithm (NHIA) uses a combination of standard variables to directly or indirectly classify cases as Hispanic for analytic purposes. It is possible to separate Hispanic ancestral subgroups (e.g., Mexican) when indirect assignment results from birthplace information but not from surname match. The algorithm uses the following standard variables: Spanish/Hispanic Origin [190], Name--Last [2230], Name--Maiden [2390], Birthplace [250], Race 1 [160], IHS Link [192], and Sex [220].

Code 7 (Spanish surname only) of the Spanish/Hispanic Origin [190] data item became effective with 1994 diagnoses. For greater detail, please refer to the technical documentation:

<http://www.naacr.org/dat#NHIA>.

#### Rationale

Sometimes despite best efforts to obtain complete information directly from the medical record, information is not available and is reported to the cancer registry as a missing data item. With regard to Hispanic ethnicity, some cancer registries have found it necessary to rely on indirect methods to populate this data element. Registries often have significant numbers or proportions of Hispanic populations in their jurisdiction.

#### Codes

- 0 Non-Hispanic
- 1 Mexican, by birthplace or other specific identifier
- 2 Puerto Rican, by birthplace or other specific identifier
- 3 Cuban, by birthplace or other specific identifier
- 4 South or Central American (except Brazil), by birthplace or other specific identifier
- 5 Other specified Spanish/Hispanic origin (includes European; excludes Dominican Republic), by birthplace or other specific identifier
- 6 Spanish, NOS; Hispanic, NOS; Latino, NOS
- 7 NHIA surname match only
- 8 Dominican Republic
- Blank Algorithm has not been run

*Note:* Code 8 was added in Standards Volume II Version 10.2 effective January 2005.

#### Considerations for Use:

Blank values are allowed for states that chose not to include data for NHIA in this file. Data for NPCR registries that are published in USCS use this variable. For age-adjusted rates by ethnicity, the user-specified variable “Origin recode NHIA (Hispanic/Non-Hispanic)” should be used.

When analyzing data at the state level, Hispanic ethnicity cannot be broken out for Delaware, Kentucky, and Massachusetts. Race and ethnicity combinations—white Hispanic, white non-Hispanic, black Hispanic, and black non-Hispanic—cannot be broken out for Arkansas, Delaware, Kentucky,

Massachusetts, and Pennsylvania. States are given the right to suppress ethnicity-specific data every submission year.

## Section: Demographic Data Items

### IHS Link

#### IHS Link

SAS Alternate Name	Length	Source of Standard
I192_IHS	1	NAACCR Item #192

#### Description

This variable captures the results of the linkage of the registry database with the Indian Health Service patient registration database.

#### Rationale

The IHS linkage identifies cancer cases among American Indians/Alaskan Natives who were misclassified as non-Indian in the registry database in order to improve the quality of cancer surveillance data on American Indians/Alaskan Natives in individual registries and in all registries as a whole. The goal is to improve cancer incidence data for American Indians/Alaskan Natives in the United States Cancer Statistics by use of this variable as well as the race variable.

#### Codes

0 Record sent for linkage, no IHS match

1 Record sent for linkage, IHS match

Blank Record not sent for linkage or linkage result pending

#### Considerations for Use:

NPCR registries with one or more IHS Contract Health Service Delivery Area (CHSDA) county are required to link their database with the IHS patient registration database on an annual basis. SEER-only registries (Connecticut, Hawaii, Iowa, New Mexico, Utah) generally link their database with the IHS database on an annual basis. Those registries **not** included in the following list may elect to link with IHS annually, but are required to link every five years. Blank values are allowed for states without CHSDA counties that chose not to link with IHS annually or chose to not include data for American Indians/Alaskan Natives in this file. Data for NPCR registries that are published in USCS use this variable. Population data are not available for this variable. For age-adjusted rates by race, the variable "NPCR Race Recode" should be used.

Alabama	Massachusetts	Oregon
Alaska	Michigan	Pennsylvania
Arizona	Minnesota	Rhode Island
California	Mississippi	South Carolina
Colorado	Montana	South Dakota
Florida	Nebraska	Texas
Idaho	Nevada	Washington
Indiana	New York	Wisconsin
Kansas	North Carolina	Wyoming
Louisiana	North Dakota	
Maine	Oklahoma	

## Section: Demographic Data Items Stateraceethncl

### Stateraceethncl

SAS Alternate Name	Length	Source of Standard
Stateraceethncl	1	NAACCR Item #192

### Description

This variable was created specifically for this database. It provides the selection of states that are eligible to be included in a state-level analysis of race and ethnicity.

### Considerations for use

- States have the option to suppress race-specific and Hispanic ethnicity-specific data every submission year. While these states can be included in an aggregated analysis, the affected state’s race and ethnicity information cannot be reported at the state level.
- The following states have state-level race or ethnicity data presentation restrictions:
  - Data for American Indians and Alaska Natives cannot be displayed for Delaware, Illinois, Kansas, Kentucky, New Jersey, and New York.
  - Data for Asians and Pacific Islanders cannot be displayed for Arkansas, Delaware, Kansas, and Kentucky.
  - Hispanic ethnicity data cannot be displayed for Arkansas, Delaware, Kentucky, and Massachusetts.
  - Race and ethnicity combinations—white Hispanic, white non-Hispanic, black Hispanic, and black non-Hispanic—cannot be displayed for Arkansas, Delaware, Kansas, Kentucky, Massachusetts, and Pennsylvania.
- For more information, please refer to the “Race Recode for USCS” and “Origin recode NHIA (Hispanic, Non-Hisp)” variable descriptions in this document.

## Section: Demographic Data Items

### Sex

#### Sex

SAS Alternate Name	Length	Source of Standard
I220_Sex	1	NAACCR Item #220

#### Description

Code for the sex of the patient.

#### Codes

- 1 Male
- 2 Female
- 3 Other (hermaphrodite)
- 4 Transsexual
- 9 Not stated/Unknown

#### Considerations for Use:

- To get the correct population denominator, “female” must be selected when analyzing female-specific cancers (such as ovarian cancer or female breast cancer) and “male” for male-specific cancers (such as prostate cancer).
- Due to small case counts and the lack of an associated population file, cases for sex other than male or female are excluded from this database.

## Section: Demographic Data Items

### Age at Diagnosis

#### Age at Diagnosis

SAS Alternate Name	Length	Source of Standard
I230_AgeDx	3	NAACCR Item #230

#### Description

Age of the patient at diagnosis in complete years.

#### Considerations for Use:

Population data are not available for this variable and is provided only in the 5-year age groups. This variable is used to create the Age Recode. Age at diagnosis in complete years should not be used for analysis.



## Section: Demographic Data Items

### Age Recode

#### Age Recode

SAS Alternate Name	Length	Source of Standard
AgeRec	2	Derived based upon NAACCR Item #230

#### Description

A standard grouping of age at diagnosis into 19 categories (<1, 1-4, 5-9, ...75-79, 80-84, 85+).

For further information on creating this variable, see the SAS statements in Appendix I.

#### Considerations for Use:

None noted.

## Section: Demographic Data Items

### Birth Date

#### Birth Date

SAS Alternate Name	Length	Source of Standard
I240_DOB	4	Derived based upon NAACCR Item #240

#### Description

Year of birth of the patient.

#### Considerations for Use:

The month and day of birth are not provided for confidentiality reasons; if age is over 99, then year of birth is recorded.

## Section: Cancer Identification Data Items

### Sequence Number – Central

#### Sequence Number – Central

SAS Alternate Name	Length	Source of Standard
I380_SeqNoCntrl	2	NAACCR Item #380

#### Description

Code indicates the sequence of all reportable neoplasms over the lifetime of the person. Each primary neoplasm (not progression or recurrences) is assigned a different number. Sequence Number 00 indicates that the person has had only one *in situ* or one malignant neoplasm as defined by the Federal reportable list (regardless of central registry reference date). Sequence Number 01 indicates the first of two or more reportable neoplasms, 02 indicates the second of two or more reportable neoplasms, and so on. Because the time period of Sequence Number is a person's lifetime, reportable neoplasms not included in the central registry (those that occur outside the registry catchment area or before the reference date) also are allotted a sequence number. For example, a registry may contain a single record for a patient with a sequence number of 02 because the first reportable neoplasm preceded the central registry's reference date or was diagnosed and treated in another state.

#### Reporting Requirements: Federally Required and State/Province Defined

The Federal standard defining the reportable neoplasms is described in the NAACCR Volume II Data Standards and Data Dictionary Chapter III, Standards For Tumor Inclusion and Reportability. It is assumed that this shared standard is the "minimum" definition of reportability. Individual central cancer registries may define additional neoplasms as reportable. Numeric codes in the 00-59 range indicate the sequence of neoplasms of *in situ* or malignant behavior (2 or 3) at the time of diagnosis, which NPCR standards require to be reported. Codes 60 to 87 indicate the sequence of non-malignant tumors (as defined in Chapter III) and any other neoplasms that the central registry has defined as reportable. Neoplasms required by NPCR with an *in situ* or malignant behavior at the time of diagnosis are sequenced completely independently of this higher-numbered category.

#### Rationale

The purpose of sequencing based on the patient's lifetime is to truly identify the 00s, the people who only had one malignant primary in their lifetime for survival analysis. If a central registry sequences by just what is reported to them, then it will be unclear whether 00 means the person only had one malignant primary in his lifetime or the person had one malignant primary since the central registry started collecting data. The Federally required reportable list has changed throughout the years, so the registry must use the appropriate reportable list for the year of diagnosis. The central registry reference date will not affect Sequence Number-Central.

#### Codes

*In Situ*/Malignant as Federally Required based on Diagnosis Year:

- 00 One primary in the patient's lifetime
- 01 First of two or more primaries
- 02 Second of two or more primaries
- ..
- ..
- 59 Fifty-ninth or higher of fifty-nine or more primaries
- 99 Unspecified or unknown sequence number of federally required *in situ* or malignant tumors.  
Sequence number 99 can be used if there is a malignant tumor and its sequence number is

unknown. If there is known to be more than one malignant tumor, then the tumors must be sequenced.

Non-malignant Tumor as Federally Required based on Diagnosis Year or State/Province Defined:

- 60 One non-malignant tumor or central registry-defined neoplasm
- 61 First of two or more non-malignant tumor or central registry-defined neoplasms
- 62 Second of two or more non-malignant tumor or central registry-defined neoplasms
- ...
- 88 Unspecified or unknown sequence number for non-malignant tumor or central registry-defined neoplasms. (Sequence number 88 can be used if there is a non-malignant tumor and its sequence number is unknown. If there is known to be more than one non-malignant
- 98 Cervix carcinoma *in situ* (CIS)/CIN III, Diagnosis Years 1996-2002.

The table that follows shows which sequence number series to use by type of neoplasm.

<b>Neoplasm</b>	<b>SeqNum-Central</b>
<b><i>In Situ</i>/Malignant as Federally Required based on Diagnosis Year</b>	<b>(Numeric Series)</b>
<i>In Situ</i> (behavior code = 2) (Cervix CIS/CIN III, Diagnosis Year before 1996) (includes VIN III, VAIN III, AIN III)	00 -- 59
Malignant (behavior code = 3)	00 -- 59
Juvenile Astrocytoma, Diagnosis Year 2001+ (*)	00 -- 59
Invasive following <i>In Situ</i> --New primary as defined by CoC	00 -- 59
Invasive following <i>In Situ</i> --New primary as defined by SEER	00 -- 59
Unspecified Federally Required Sequence Number or Unknown	99
<b>Non-malignant Tumor as Federally Required based on Diagnosis Year or State/Province Registry-Defined</b>	
Examples:	
Non-malignant Tumor/Benign Brain	60 -- 87
Borderline Ovarian, Diagnosis Year 2001+	60 -- 87
Other Borderline/Benign	60 -- 87
Skin SCC/BCC	60 -- 87
PIN III	60 -- 87
Cervix CIS/CIN III, Diagnosis Year 2003+	60 -- 87
Unspecified Non-malignant Tumor or Central Registry-Defined Sequence Number	88
Cervix CIS/CIN III, Diagnosis Year 1996-2002	98

\*Juvenile astrocytomas should be reported as 9421/3.

*Note:* Conversion Guidance: The sequence numbers for neoplasms whose histologies were associated with behavior codes that changed from *in situ*/malignant to benign/borderline or vice versa during the conversion from ICD-O-2 to ICD-O-3 should not be re-sequenced.

## Section: Cancer Identification Data Items Date of Diagnosis

### Date of Diagnosis

SAS Alternate Name	Length	Source of Standard
I390_DateDX	8	Derived based upon NAACCR Item #390

### Description

Date of initial diagnosis by a recognized medical practitioner for the cancer being reported whether clinically or microscopically confirmed. This dataset contains records with a diagnosis year of 1998-2013.

### Considerations for Use:

The day of diagnosis is not provided for confidentiality reasons. Only valid portions of the date are included in this dataset. Below are the common formats to handle the situation where only certain components of date are known.

YYYYMM – when year and month are known and valid

YYYY – when year is known and valid, and month is unknown

Blank – when no known date applies

## Section: Cancer Identification Data Items

### Primary Site

#### Primary Site

SAS Alternate Name	Length	Source of Standard
I400_Site	4	NAACCR Item #400

#### Description

Code for the primary site of the tumor being reported using ICD-O-3.

#### Considerations for Use:

Reference: Fritz A et al., editors. International Classification of Diseases for Oncology. Third Edition. Geneva: World Health Organization; 2000.

See ICD-O-3,<sup>14</sup> or ICD-O-3,<sup>13</sup> Topography Section, for the codes for primary site.

Consider reviewing the variables “Primary Site Recode” or “Primary Site Recode with Kaposi Sarcoma and Mesothelioma” before using the directly coded primary site. For more information on the SEER primary site recodes, see <http://seer.cancer.gov/siterecode/>.

## Section: Cancer Identification Data Items Laterality

### Laterality

SAS Alternate Name	Length	Source of Standard
I410_Laterality	1	NAACCR Item #410

### Description

Code for the side of a paired organ, or the side of the body on which the reportable tumor originated. This applies to the primary site only.

Starting with cases diagnosed January 1, 2004, and later, laterality is coded for select invasive, benign, and borderline primary intracranial and CNS tumors.

### Codes

- 0 Not a paired site
- 1 Right: origin of primary
- 2 Left: origin of primary
- 3 Only one side involved, right or left origin unspecified
- 4 Bilateral involvement at time of diagnosis, lateral origin unknown for a single primary; or both ovaries involved simultaneously, single histology; bilateral retinoblastomas; bilateral Wilms tumors
- 5 Paired site: midline tumor (effective with 1/1/2010 dx)
- 9 Paired site, but no information concerning laterality

## Section: Cancer Identification Data Items Grade

### Grade

SAS Alternate Name	Length	Source of Standard
I440_Grade	1	NAACCR Item #440

### Description

Code for the grade or degree of differentiation of the reportable tumor. For lymphomas and leukemias, field also is used to indicate T-, B-, Null-, or NK-cell origin.

### Codes

#### Histologic Grading and Differentiation

- |   |           |   |
|---|-----------|---|
| 1 | Grade I   | Well differentiated<br>Differentiated, NOS  |
| 2 | Grade II  | Moderately differentiated<br>Moderately well differentiated<br>Intermediate differentiation |
| 3 | Grade III | Poorly differentiated   |
| 4 | Grade IV  | Undifferentiated<br>Anaplastic  |

#### Immunophenotype Designation for Lymphomas and Leukemias

- |   |                          |
|---|--------------------------|
| 5 | T-cell                   |
| 6 | B-cell                   |
| 7 | Null cell                |
| 8 | NK (natural killer) cell |

*Comment:* Use the most recent hematopoietic and lymphoid rules for assigning grades 5-8.

- |   |  |
|---|--|
| 9 | Grade/differentiation unknown, not stated, or not applicable |
|---|--|

### Considerations for Use:

Reference: Fritz A et al., editors. International Classification of Diseases for Oncology. Third Edition. Geneva: World Health Organization; 2000.

The practice of grading varies greatly among pathologists throughout the world, and many malignant tumors are not routinely graded. Since different grading systems may be used, users should review the site-specific modules available at: [http://training.seer.cancer.gov/modules\\_site\\_spec.html](http://training.seer.cancer.gov/modules_site_spec.html) and the most current FORDS manual (<http://www.facs.org/cancer/coc/fordsmanual.html>). Each module has an abstracting, coding, and staging section, which has a morphology and grading sub-section. Some modules, but not all, contain notes about the grading system that may have been used to code grade. Currently, this dataset does not contain a variable to differentiate a specific grading system from another one if more than two grading systems are mentioned.

Diagnostic practices also influence coding practices. For example, preliminary analysis of tumor grade for prostate cancer showed an artificial increase in higher grade from 2002 to 2003. Additional review showed that the International Society of Urologic Pathologists (ISUP) in conjunction with the WHO made a series of recommendations for modification of the Gleason grading system to reflect



contemporary knowledge, alleviate uncertainty, and promote uniformity in its application. One recommendation was for pathologists to report all higher tertiary grade components of the tumor as part of the Gleason score. Another recommendation was made for reporting of any higher grade cancer, no matter how small quantitatively. More information about grade migration is available:

1. Luthringer DJ, Gross M. Gleason Grade Migration: Changes in Prostate Cancer Grade in the Contemporary Era. *PCRI Insights* 2001; 9(3). Available at: [http://www.prostatecancer.org/education/staging/Luthringer\\_GleasonGradeMigration.html](http://www.prostatecancer.org/education/staging/Luthringer_GleasonGradeMigration.html).
2. Jani AB, Master VA, Rossi PJ, Liauw SL, Johnstone PAS. Grade migration in prostate cancer: an analysis using the Surveillance, Epidemiology, and End Results registry. *Prostate Cancer and Prostatic Diseases* 2007; 10: 347–351.
3. Thompson IM, Canby-Hagino E, Lucia MS. Stage Migration and Grade Inflation in Prostate Cancer: Will Rogers Meets Garrison Keillor. *Journal of the National Cancer Institute* 2005; 97(17): 1236-7.

## Section: Cancer Identification Data Items Diagnostic Confirmation

### Diagnostic Confirmation

SAS Alternate Name	Length	Source of Standard
I490_DxConf	1	NAACCR Item #490

### Description

Code for the best method of diagnostic confirmation of the cancer being reported at any time in the patient's history.

### Rationale

Diagnostic confirmation is useful to calculate rates based on microscopically confirmed cancers. Full incidence calculations must also include tumors that are only confirmed clinically. The percentage of tumors that are not microscopically confirmed is an indication of whether case finding is including sources outside of pathology reports.

### Codes

- 1 Positive histology
- 2 Positive cytology
- 3 Positive histology PLUS – positive immunophenotyping AND/OR positive genetic studies (Used only for hematopoietic and lymphoid neoplasms M-9590/3-9992/3)
- 4 Positive microscopic confirmation, method not specified
- 5 Positive laboratory test/marker study
- 6 Direct visualization without microscopic confirmation
- 7 Radiography and/or other imaging techniques without microscopic confirmation
- 8 Clinical diagnosis only (other than 5, 6, or 7)
- 9 Unknown whether or not microscopically confirmed; death certificate only

*Note:* Code 3 (used only for hematopoietic and lymphoid neoplasms M-9590/3-9992/3) was adopted for use effective with 2010 diagnoses.

### Considerations for Use:

None noted.

## Section: Cancer Identification Data Items

### Type of Reporting Source

#### Type of Reporting Source

SAS Alternate Name	Length	Source of Standard
I500_TypeRptSrc	1	NAACCR Item #500

#### Description

This variable codes the source documents used to abstract the majority of information on the tumor being reported. This may not be the source of original case finding (for example, if a case is identified through a pathology laboratory report review and all source documents used to abstract the case are from the physician's office, code this item 4).

#### Rationale

The code in this field can be used to explain why information may be incomplete on a tumor. For example, death certificate only cases have unknown values for many data items, so one may want to exclude them from some analyses. The field also is used to monitor the success of non-hospital case reporting and follow-back mechanisms. All population-based registries should have some death certificate-only cases where no hospital admission was involved, but too high a percentage can imply both shortcomings in case-finding and that follow-back to uncover missed hospital reports was not complete.

#### Considerations for Use:

Codes are assigned in the following priority order: 1, 2, 8, 4, 3, 5, 6, 7. This prioritizes laboratory reports over nursing home reports. The source facilities included in the code 1 (hospital inpatient and outpatient) were split in 2006 between codes 1, 2, and 8. Sources coded with '8' would include, but would not be limited to, outpatient surgery and nuclear medicine services.

#### Codes

- 1 Hospital inpatient; Managed health plans with comprehensive, unified medical records
- 2 Radiation Treatment Centers or Medical Oncology Centers (hospital-affiliated or independent)
- 3 Laboratory only (hospital-affiliated or independent)
- 4 Physician's office/private medical practitioner (LMD)
- 5 Nursing/convalescent home/hospice
- 6 Autopsy only
- 7 Death certificate only
- 8 Other hospital outpatient units/surgery centers

## Section: Cancer Identification Data Items Histologic Type ICD-O-3

### Histologic Type ICD-O-3

SAS Alternate Name	Length	Source of Standard
I522_HistTypeICDO3	4	NAACCR Item #522

#### Description

Codes for the histologic type of the tumor being reported using ICD-O-3. ICD-O-3 was adopted as the standard coding system for tumors diagnosed in 2001 and later. Tumors diagnosed prior to 2001 have been converted from ICD-O-2. Effective with cases diagnosed in 2010 and forward, this item also includes codes for new terms as per the 2008 WHO Hematopoietic/Lymphoid publication.

#### Considerations for Use:

Reference: Fritz A et al., editors. International Classification of Diseases for Oncology. Third Edition. Geneva: World Health Organization; 2000.

See ICD-O-3, Morphology Section and the SEER Hematopoietic database (<http://seer.cancer.gov/tools/heme/>).

## Section: Cancer Identification Data Items Behavior Code ICD-O-3

### Behavior Code ICD-O-3

SAS Alternate Name	Length	Source of Standard
I523_BehavICDO3	1	NAACCR Item #523

### Description

Code for the behavior of the tumor being reported using ICD-O-3. ICD-O-3 was adopted as the standard coding system for tumors diagnosed in 2001 and later. Tumors diagnosed prior to 2001 have been converted from ICD-O-2.

Juvenile astrocytoma is coded as borderline in ICD-O-3; North American registries report as 9421/3.

### Codes

- 0 Benign
- 1 Uncertain whether benign or malignant
  - Borderline malignancy
  - Low malignant potential
  - Uncertain malignant potential
- 2 Carcinoma in situ
  - Intraepithelial
  - Noninfiltrating
  - Noninvasive
- 3 Malignant, primary site
- 6 Malignant, metastatic site
  - Malignant, secondary site
- 9 Malignant, uncertain whether primary or metastatic site

### Considerations for Use:

Reference: Fritz A et al., editors. International Classification of Diseases for Oncology. Third Edition. Geneva: World Health Organization; 2000.

## Section: Cancer Identification Data Items Behavior Recode for Analysis

### Behavior Recode for Analysis

SAS Alternate Name	Length	Source of Standard
Behavior_Recode_For_Analysis	8	Derived based upon NAACCR Items #400, #522, and #523

### Description

The purpose of this variable is to allow for selection of behavior codes that are consistent between ICD-O-2 and ICD-O-3. ICD-O-3 is used to code cases diagnosed on or after January 1, 2001. Codes that are newly malignant in ICD-O-3 and codes that are no longer malignant in ICD-O-3 (e.g., borderline ovarian cancers) show up as invalid.

For further information on creating this variable, see the SAS statements in Appendix I.

### Considerations for Use:

See Appendix 6 in ICD-O-3 for a list of histologies that changed behavior. Reference: Fritz A et al., editors. International Classification of Diseases for Oncology. Third Edition. Geneva: World Health Organization; 2000.

## Section: Cancer Identification Data Items Primary Site Recode

### Primary Site Recode

SAS Alternate Name	Length	Source of Standard
Site_Recode_ICD_O_3_WHO_2008	8	Derived based upon NAACCR Items #400 and #522

### Description

The values of the primary site recode variable are based on the primary site and histology data fields submitted by the registries. The site recode variables define the major cancer sites that are commonly used in the reporting of cancer incidence data. This recode is defined by the SEER program.

### Codes

Reference for Primary Site Recode for ICD-O-3 is:

[http://seer.cancer.gov/siterecode/icdo3\\_dwhoheme/index.html](http://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.html)

### Considerations for Use:

None noted.

## Section: Cancer Identification Data Items Primary Site Recode with Mesothelioma and Kaposi Sarcoma

### Primary Site Recode with Mesothelioma and Kaposi Sarcoma

SAS Alternate Name	Length	Source of Standard
SiterecwithKaposiandmesothelio	8	Derived based upon NAACCR Items #400 and #522

#### Description

The values of the primary site recode variable are based on the primary site and histology data fields submitted by the registries. The site recode variables define the major cancer sites that are commonly used in the reporting of cancer incidence data. This recode pulls out Mesothelioma and Kaposi Sarcoma as separate categories and is the recode used by CDC, NCI, and NAACCR in their surveillance publications. This recode is defined by the SEER program.

For further information on creating this variable, see the SAS statements in Appendix I.

#### Codes

Reference for Primary Site Recode for ICD-O-3 is:

[http://seer.cancer.gov/siterecode/icdo3\\_dwhoheme/index.html](http://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.html)

#### Considerations for Use:

None noted.



## Section: Cancer Identification Data Items SEER-Modified International Classification of Childhood Cancer (ICCC) Recode

### SEER-Modified International Classification of Childhood Cancer (ICCC) Recode

SAS Alternate Name	Length	Source of Standard
ICCCSiteRecExtendedICDO3WHO200	8	Derived based upon NAACCR Items #400, #522, and #523

#### Description

The values of the SEER-modified International Classification of Childhood Cancer recode variable are based on the primary site and histology data fields submitted by the registries. The classification of childhood cancer is based on tumor morphology rather than, as for adults, the site of the tumor. These recodes were adapted by the SEER program from groupings developed by the World Health Organization.

#### Codes

Note that beginning with data released in 2006, the grouping of childhood cancers is based on ICD-O-3 instead of ICD-O-2. Reference for the ICCC recodes is:

<http://seer.cancer.gov/iccc/>

#### Considerations for Use:

Note that beginning with data released in 2006, the grouping of childhood cancers is based on ICD-O-3 instead of ICD-O-2.

## Section: Stage/Prognostic Factors Data Items SEER Summary Stage 2000

### SEER Summary Stage 2000

SAS Alternate Name	Length	Source of Standard
I759_SS2000	1	NAACCR Item #759

#### Description

Code for the summary stage at the initial diagnosis or treatment of the reportable tumor. For site-specific definitions of categories, see *SEER Summary Staging Manual 2000*.

Summary stage should include all information available through completion of surgery (ies) in the first course of treatment or within 4 months of diagnosis in the absence of disease progression, whichever is longer.

#### Rationale

Stage information is important when evaluating the effects of cancer control programs. It is crucial in understanding whether changes over time in incidence rates or outcomes are due to earlier detection of the cancers. In addition, cancer treatment cannot be studied without knowing the stage at diagnosis.

#### Codes

- 0 *In situ*
- 1 Localized
- 2 Regional, direct extension only
- 3 Regional, regional lymph nodes only
- 4 Regional, direct extension and regional lymph nodes
- 5 Regional, NOS
- 7 Distant
- 8 Not applicable
- 9 Unstaged

*Note:* Code 8 was added effective with cases diagnosed in 2004 and forward to be used when there is not an applicable code to reflect stage (e.g., benign brain, borderline ovarian).

*Note:* See also the item Derived SS2000 [3020] for the value of SEER Summary Stage 2000 as generated by the collaborative Staging algorithm.

#### Considerations for Use:

Summary stage is a required variable. The correct data item to use (and corresponding code manual) is determined by the year in which the cancer was diagnosed. Summary Stage 2000 is used for tumors diagnosed 2001-2003.

For cases diagnosed 2004-2013, Summary Stage 2000 is derived from information coded in the Collaborative Stage Data Collection System. In certain circumstances when information is not available to calculate the Derived Summary Stage 2000, NPCR permits the use of Summary Stage 2000 for diagnosis years 2004-2013. As a result, when stage information is required, it is recommended that and the "Merged Summary Stage 2000" be used to account for missing information in Derived Summary Stage 2000.

Cases diagnosed before January 1, 2001, are assigned a summary stage according to *SEER Summary Stage Guide 1977*, and the code is reported in SEER Summary Stage 1977 [760].

To assess the effect of changes between Summary Stage 2000 and Summary Stage 1977 on a particular site, there are two references: 1) Phillips, JL, coordinator. Data Effects of the Changes in 2000 and 2) Summary Stage Comparability Report, 2005 from the Collaborative Research Working Group of NAACCR. Both are located on the NAACCR web site at [www.naacr.org](http://www.naacr.org).

To study historical trends in stage, Summary Stage should be selected according to the following table:

Diagnosis Years	Summary Stage Version
1998-2000	Summary Stage 1977
2001-2003	Summary Stage 2000
2004-2014	Derived Summary Stage 2000 (see note above)

See notes on page 3 for additional information.

## Section: Stage/Prognostic Factors Data Items SEER Summary Stage 1977

### SEER Summary Stage 1977

SAS Alternate Name	Length	Source of Standard
I760_SS1977	1	NAACCR Item #760

#### Description

Code for summary stage at the initial diagnosis or treatment of the reportable tumor. This has traditionally been used by central registries to monitor time trends. For site-specific definitions of categories, see the SEER Summary Staging Guide.

SEER Summary Stage 1977 is limited to information available within 2 months of the date of diagnosis. NAACCR approved extension of this time period to 4 months for prostate tumors diagnosed beginning January 1, 1995.

#### Rationale

Stage information is important when evaluating the effects of cancer control programs. It is crucial for understanding whether changes over time in incidence rates or outcomes are due to earlier detection of the cancers. In addition, cancer treatment cannot be studied without knowing the stage at diagnosis.

To study historical trends in stage, the coding system must be relatively unchanged (stable) over time. AJCC's TNM system is updated periodically to maintain clinical relevance with changes in diagnosis and treatment. The surveillance registries often rely on the Summary Stage, which they consider to be more "stable." Summary Stage has been in widespread use, either as the primary staging scheme or a secondary scheme, in most central and hospital registries since 1977.

#### Codes

- 0 In situ
- 1 Localized
- 2 Regional, direct extension only
- 3 Regional, regional lymph nodes only
- 4 Regional, direct extension and regional lymph nodes
- 5 Regional, NOS
- 7 Distant
- 8 Not applicable
- 9 Unstaged

*Note:* Code 8 was added effective with cases diagnosed in 2004 and forward to be used when there is not an applicable code to reflect stage (e.g., benign brain, borderline ovarian).

#### Considerations for Use:

Summary stage is a required variable. The correct data item to use (and corresponding code manual) is determined by the year in which the cancer was diagnosed. Summary Stage 2000 is used for tumors diagnosed 2001-2003.

For cases diagnosed 2004-2013, Summary Stage 2000 is derived from information coded in the Collaborative Stage Data Collection System. In certain circumstances when information is not available to calculate the Derived Summary Stage 2000, NPCR permits the use of Summary Stage 2000 for

diagnosis years 2004-2013. As a result, when stage information is required, it is recommended that the “Merged Summary Stage 2000” variable be used to account for missing information in Derived Summary Stage 2000.

Cases diagnosed before January 1, 2001, are assigned a summary stage according to *SEER Summary Stage Guide 1977*, and the code is reported in SEER Summary Stage 1977 [760].

To assess the effect of changes between Summary Stage 2000 and Summary Stage 1977 on a particular site, there are two references: 1) Phillips, JL, coordinator. Data Effects of the Changes in 2000 and 2) Summary Stage Comparability Report, 2005 from the Collaborative Research Working Group of NAACCR. Both are located on the NAACCR web site at [www.naacr.org](http://www.naacr.org).

To study historical trends in stage, Summary Stage should be selected according to the following table:

Diagnosis Years	Summary Stage Version
1998-2000	Summary Stage 1977
2001-2003	Summary Stage 2000
2004-2014	Derived Summary Stage 2000 (see note above)

See notes on page 3 for additional information.

## Section: Stage/Prognostic Factors Data Items CS Extension

### CS Extension

SAS Alternate Name	Length	Source of Standard
I2810_CSExt	3	NAACCR Item #2810

### Description

This data item belongs to the Collaborative Stage (CS) Data Collection System. The CS is based on the *AJCC Cancer Staging Manual*, 6<sup>th</sup> and 7<sup>th</sup> editions, as well as the SEER Summary Stage, 1977 and 2000. CS Extension identifies primary tumor growth (extension) within the organ of origin or its extension into neighboring organs. For certain sites, such as ovary, discontinuous metastasis is coded in *CS Extension*. Site-specific codes provide extensive detail describing disease extent.

### Rationale

Tumor extension at diagnosis is a prognostic indicator used by Collaborative Staging to derive SEER Summary Stage codes.

**Codes (See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org>) for rules and site-specific codes and coding structures.)**

### Considerations for Use:

This variable provides detailed information and allows stratification that may not be available when using the stage grouping. Caution should be used to avoid stratification that may introduce biases due to small case counts.

## Section: Stage/Prognostic Factors Data Items

### CS Lymph Nodes

#### CS Lymph Nodes

SAS Alternate Name	Length	Source of Standard
I2830_CSlymphNodes	3	NAACCR Item #2830

#### Description

This data item belongs to the Collaborative Stage (CS) Data Collection System. The CS is based on the *AJCC Cancer Staging Manual*, 6<sup>th</sup> and 7<sup>th</sup> editions, as well as the SEER Summary Stage, 1977 and 2000. CS Lymph Nodes is site-specific and identifies the regional lymph nodes involved with cancer at the time of diagnosis.

#### Rationale

The involvement of specific regional lymph nodes is a prognostic indicator used by Collaborative Staging to derive SEER Summary Stage codes.

**Codes (See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org>) for rules and site-specific codes and coding structures.)**

#### Considerations for Use:

This variable provides detailed information and allows stratification that may not be available when using the stage grouping. Caution should be used to avoid stratification that may introduce biases due to small case counts.

## Section: Stage/Prognostic Factors Data Items CS Mets at DX

### CS Mets at DX

SAS Alternate Name	Length	Source of Standard
I2850_CSMetsDx	3	NAACCR Item #2850

#### Description

This data item belongs to the Collaborative Stage (CS) Data Collection System. The CS is based on the *AJCC Cancer Staging Manual*, 6<sup>th</sup> and 7<sup>th</sup> editions, as well as the SEER Summary Stage, 1977 and 2000. CS Lymph Nodes is site-specific and identifies the site(s) of metastatic involvement at the time of diagnosis.

#### Rationale

The presence of metastatic disease at diagnosis is an independent prognostic indicator used by Collaborative Staging to derive SEER Summary Stage codes.

**Codes (See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org>) for rules and site-specific codes and coding structures.)**

#### Considerations for Use:

This variable provides detailed information and allows stratification that may not be available when using the stage grouping. Caution should be used to avoid stratification that may introduce biases due to small case counts.



## Section: Stage/Prognostic Factors Data Items

### CS Site Specific Factor 1

#### CS Site Specific Factor 1

SAS Alternate Name	Length	Source of Standard
I2880_CSSSF1	3	NAACCR Item #2880

#### Description

This data item belongs to the Collaborative Stage (CS) Data Collection System. The CS is based on the *AJCC Cancer Staging Manual*, 6<sup>th</sup> and 7<sup>th</sup> editions, as well as the SEER Summary Stage, 1977 and 2000. CS Site Specific Factor 1 (SSF1) identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

#### Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive SEER Summary Stage codes for particular site-histology schema.

**Codes (The information recorded in CS Site-Specific Factor 1 differs for each anatomic site. See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org>) for rules and site-specific codes and coding structures.)**

#### Considerations for Use:

This variable provides detailed information and allows stratification that may not be available when using the stage grouping. Caution should be used to avoid stratification that may introduce biases due to small case counts.

NPCR requires CS SSF1 for the female breast, brain/CNS, lung, pleura, and retinoblastoma primary sites/histologies only. SEER requires CS SSF1 for several primary sites/histologies. Though CS SSF1 may be included in the dataset for other primary sites/histologies, the CS SSF1 information for those primary sites/histologies reported by NPCR central cancer registries was reported as it was available and is considered unreliable at this time.

## Section: Stage/Prognostic Factors Data Items

### CS Site Specific Factor 2

#### CS Site Specific Factor 2

SAS Alternate Name	Length	Source of Standard
I2890_CSSSF2	3	NAACCR Item #2890

#### Description

This data item belongs to the Collaborative Stage (CS) Data Collection System. The CS is based on the *AJCC Cancer Staging Manual*, 6<sup>th</sup> and 7<sup>th</sup> editions, as well as the SEER Summary Stage, 1977 and 2000. CS Site Specific Fact 2 (SSF2) identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

#### Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive SEER Summary Stage codes for particular site-histology schema.

**Codes (The information recorded in CS Site-Specific Factor 2 differs for each anatomic site. See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org>) for rules and site-specific codes and coding structures.)**

#### Considerations for Use:

This variable provides detailed information and allows stratification that may not be available when using the stage grouping. Caution should be used to avoid stratification that may introduce biases due to small case counts.

NPCR requires CS SSF2 for the female breast and corpus uteri primary sites/histologies only. SEER requires CS SSF1 for several primary sites/histologies. Though CS SSF1 may be included in the dataset for other primary sites/histologies, the CS SSF1 information for those primary sites/histologies reported by NPCR central cancer registries was reported as it was available and is considered unreliable at this time.

## Section: Stage/Prognostic Factors Data Items

### CS Site Specific Factor 3

#### CS Site Specific Factor 3

SAS Alternate Name	Length	Source of Standard
I2900_CSSSF3	3	NAACCR Item #2900

#### Description

This data item belongs to the Collaborative Stage (CS) Data Collection System. The CS is based on the *AJCC Cancer Staging Manual*, 6<sup>th</sup> and 7<sup>th</sup> editions, as well as the SEER Summary Stage, 1977 and 2000. CS Site Specific Fact 3 (SSF3) identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

#### Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive SEER Summary Stage codes for particular site-histology schema.

**Codes (The information recorded in CS Site-Specific Factor 3 differs for each anatomic site. See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org>) for rules and site-specific codes and coding structures.)**

#### Considerations for Use:

This variable provides detailed information and allows stratification that may not be available when using the stage grouping. Caution should be used to avoid stratification that may introduce biases due to small case counts.

NPCR requires CS SSF3 for the prostate primary site/histologies only. SEER requires CS SSF1 for several primary sites/histologies. Though CS SSF1 may be included in the dataset for other primary sites/histologies, the CS SSF1 information for those primary sites/histologies reported by NPCR central cancer registries was reported as it was available and is considered unreliable at this time.

## Section: Stage/Prognostic Factors Data Items CS Site Specific Factor 15

### CS Site Specific Factor 15

SAS Alternate Name	Length	Source of Standard
I2859_CSSSF15	3	NAACCR Item #2869

#### Description

This data item belongs to the Collaborative Stage (CS) Data Collection System. The CS is based on the *AJCC Cancer Staging Manual*, 6<sup>th</sup> and 7<sup>th</sup> editions, as well as the SEER Summary Stage, 1977 and 2000. CS Site Specific Fact 15 (SSF15) identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

#### Rationale

Site-specific factors are used to record additional staging information needed by Collaborative Staging to derive SEER Summary Stage codes for particular site-histology schema.

**Codes (The information recorded in CS Site-Specific Factor 15 differs for each anatomic site. See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org>) for rules and site-specific codes and coding structures.)**

#### Considerations for Use:

This variable provides detailed information and allows stratification that may not be available when using the stage grouping. Caution should be used to avoid stratification that may introduce biases due to small case counts.

NPCR requires CS SSF15 for the female breast primary site/histologies only. SEER requires CS SSF1 for several primary sites/histologies. Though CS SSF1 may be included in the dataset for other primary sites/histologies, the CS SSF1 information for those primary sites/histologies reported by NPCR central cancer registries was reported as it was available and is considered unreliable at this time.

## Section: Stage/Prognostic Factors Data Items

### CS Site Specific Factor 25

#### CS Site Specific Factor 25

SAS Alternate Name	Length	Source of Standard
I2879_CSSSF25	3	NAACCR Item #2879; AJCC

#### Description

This data item belongs to the Collaborative Stage (CS) Data Collection System. The CS is based on the *AJCC Cancer Staging Manual*, 6<sup>th</sup> and 7<sup>th</sup> editions, as well as the SEER Summary Stage, 1977 and 2000. CS Site Specific Factor 25 (SSF25) identifies additional information needed to generate stage.

#### Rationale

*CS Site-Specific Factor25* is used to discriminate between CS staging schema where site and histology alone are insufficient to identify the tumor type or location to identify the applicable staging method.

**Codes (The information recorded in CS Site-Specific Factor25 differs for each anatomic site. See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org>) for rules and site-specific codes and coding structures.)**

#### Considerations for Use:

This variable provides detailed information and allows stratification that may not be available when using the stage grouping. Caution should be used to avoid stratification that may introduce biases due to small case counts.

CS SSF25 is required for the following primary sites only.

BileDuctsDistal
BileDuctsPerihilar
CysticDuct
EsophagusGEJunction
LacrimalGland
LacrimalSac
MelanomaCiliaryBody
MelanomaIris
Nasopharynx
Peritoneum
PeritoneumFemaleGen
PharyngealTonsil
Stomach

## Section: Stage/Prognostic Factors Data Items CS Version Input Original

### CS Version Input Original

SAS Alternate Name	Length	Source of Standard
I2935_CSVerInputOrig	6	NAACCR Item #2935; AJCC

#### Description

This data item belongs to the Collaborative Stage (CS) Data Collection System. The CS is based on the *AJCC Cancer Staging Manual*, 6<sup>th</sup> and 7<sup>th</sup> editions, as well as the SEER Summary Stage, 1977 and 2000. CS Version Input Original indicates the number of the version initially used to code Collaborative Staging (CS) fields. The CS version number is returned as part of the output of the CS algorithm.

#### Rationale

Over time, the input codes and instructions for CS items may change. This item identifies the correct interpretation of input CS items.

**Codes (See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org>) for rules and site-specific codes and coding structures.)**

CS Version Input Original is a 6-digit code (e.g., 010100). The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation of results.

This item should not be blank if the CS Derived items contain values. It should be blank if the CS Derived items are empty or the CS algorithm has not been applied.

#### Considerations for Use:

None noted

## Section: Stage/Prognostic Factors Data Items

### CS Version Derived

#### CS Version Input Derived

SAS Alternate Name	Length	Source of Standard
I2936_CSVerDerived	6	NAACCR Item #2936; AJCC

#### Description

This data item belongs to the Collaborative Stage (CS) Data Collection System. The CS is based on the *AJCC Cancer Staging Manual*, 6<sup>th</sup> and 7<sup>th</sup> editions, as well as the SEER Summary Stage, 1977 and 2000. CS Version Input Derived indicates the used to derive Collaborative Staging (CS) fields and is recorded the first time the CS output fields are derived and are updated each time the CS Derived items are recomputed. The CS version number is returned as part of the output of the CS algorithm.

#### Rationale

The CS algorithm may be re-applied to compute the CS Derived items; for example, when the data are to be used for a special study, transmitted, or when an updated CS algorithm is produced. This item identifies the specific algorithm used to obtain the CS Derived values in the data record.

**Codes (See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org>) for rules and site-specific codes and coding structures.)**

CS Version Derived is a 6-digit code (e.g., 010100). The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation results.

This item should not be blank if the CS Derived items contain values. It should be blank if the CS Derived items are empty or the CS algorithm has not been applied.

#### Considerations for Use:

None noted

## Section: Stage/Prognostic Factors Data Items

### CS Input Current

#### CS Input Current

SAS Alternate Name	Length	Source of Standard
I2937_CSVerInputCur	6	NAACCR Item #2937; AJCC

#### Description

This data item belongs to the Collaborative Stage (CS) Data Collection System. The CS is based on the *AJCC Cancer Staging Manual*, 6<sup>th</sup> and 7<sup>th</sup> editions, as well as the SEER Summary Stage, 1977 and 2000. CS Input Current identifies the version used to code Collaborative Staging (CS) fields after they have been updated or recoded. This data item is recorded the first time the CS input fields are entered and should be updated each time the CS input fields are modified.

#### Rationale

Over time, the input codes and instructions for CS items may change. This item identifies the correct interpretation of input CS items.

**Codes (See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org>) for rules and site-specific codes and coding structures.)**

CS Version Input Current is a 6-digit code (e.g., 020100). The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation of results.

This item should not be blank if the CS Derived items contain values. It should be blank if the CS Derived items are empty or the CS algorithm has not been applied.

#### Considerations for Use:

None noted



## Section: Stage/Prognostic Factors Data Items Derived SEER Summary State 2000

### Derived SS2000

SAS Alternate Name	Length	Source of Standard
I3020_DerivedSS2000	1	NAACCR Item #3020; AJCC

### Description

This item is the “SEER Summary Stage 2000” derived from the CS algorithm effective with 2004 diagnosis year.

### Rationale

The Collaborative Stage Data Collection System was designed by a joint task force including representatives from SEER, ACoS, CDC, NAACCR, NCRA, CCCR, CPAC, and AJCC, to provide a single uniform set of codes and rules for coding stage information to meet the needs of all of the participating standard setters. When CS data items are coded, a computer algorithm provides the derivation of SEER Summary Stage 2000.

**Codes (See the most current version of the *Collaborative Stage Data Collection System* (<http://cancerstaging.org/cstage/manuals.html>) for rules and site-specific codes and coding structures.)**

### Considerations for Use:

Records in this dataset should have a Derived SS2000 for diagnosis years 2004-2013. This data item is usually blank for records in this dataset with a diagnosis year prior to 2004 (1998-2003). In certain circumstances when information is not available to calculate the Derived Summary Stage 2000, NPCR permits the use of Summary Stage 2000 for diagnosis years 2004-2013. As a result, when stage information is required, it is recommended that consideration be given to using both Derived Summary Stage 2000 and Summary Stage 2000 to account for missing information in Derived Summary Stage 2000. The data item SEER Summary Stage 1977 provides stage information for records with a diagnosis year of 1998-2000 and SEER Summary Stage 2000 provides stage information for records with a diagnosis year of 2001-2003.

To study historical trends in stage, Summary Stage should be selected according to the following table:

Diagnosis Years	Summary Stage Version
1998-2000	Summary Stage 1977
2001-2003	Summary Stage 2000
2004-2014	Derived Summary Stage 2000 (see note above)

Previous data quality analyses identified concerns with the information reported in this variable, such as conflicts between the coded CS Extension and Behavior variables; e.g. in situ behavior with an extension indicating an invasive lesion. It is felt that subsequent training and implementation of additional electronic data edits have greatly improved the validity and reliability of the staging information. However, particular attention should be paid to data query results and stage information should be used with caution. If there are concerns about stage distributions resulting from data queries, please contact CDC’s National Program of Cancer Registries Cancer Surveillance System lead ([dfo8@cdc.gov](mailto:dfo8@cdc.gov)).

See notes on page 3 for additional information.

## Section: Stage/Prognostic Factors Data Items Merged Summary Stage 2000

### Merged Summary Stage 2000

SAS Alternate Name	Length	Source of Standard
Merged_SumStage2000	1	NPCR, combined from NAACCR Items #759 and #3020

### Description

This is a merged stage variable created using two other variables: “SEER Summary Stage 2000,” which records stage from diagnosis years 2001–2003, and “Derived SS2000,” which records stage from diagnostic years 2004–2013. This stage variable can be used for diagnosis years 2001–2013.

### Considerations for use

- The coding logic for this merged variable is:
  - If a case was diagnosed between 2001 and 2003, the Summary Stage 2000 variable value was used.
  - If a case was diagnosed between 2004 and 2014, then the Derived Summary Stage 2000 (Derived SS2000) variable was used.
  - If the Derived Summary Stage 2000 variable was blank and a valid value was available for the Summary Stage 2000 variable, that value was used to populate the merged variable. For example, if the case was diagnosed in 2013 and Derived Summary Stage was blank, but Summary Stage had a value of local, then the merged variable was coded as local stage. Otherwise, the merged variable would be left blank.
- For more information about SEER Summary Stage 2000 and Derived SS2000 variables, please review <https://cancerstaging.org/cstage/Pages/default.aspx>.

## Section: Over-ride Flags Data Items

### Over-ride Age/Site/Morph

#### Over-ride Age/Site/Histology Inter-field Review (Inter-field Edit 15)

SAS Alternate Name	Length	Source of Standard
I1990_ORAgeSiteMorph	1	NAACCR Item #1990; SEER

#### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Inter-field Edit	Description
Age, Primary Site, Morphology ICDO3 (SEER IF15)	Identifies records with an unusual occurrence of a particular age/site/histology combination for a given age group
Age, Primary Site, Morph ICDO3--Adult (SEER)	Identifies records with an unusual occurrence of a particular age/site/histology combination for a given age group in records with an age at diagnosis $\geq 15$
Age, Primary Site, Morph ICDO3--Pediatric (NPCR)	Identifies records with an unusual occurrence of a particular age/site/histology combination for a given age group in records with an age at diagnosis 00-14

#### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See NAACCR Standards for Cancer Registries Volume II: Data Standards and Data Dictionary Chapter IV Recommended Data Edits and Software Coordination of Standards.

#### Over-ride Flag as Used in the EDITS Software Package

Some cancers occur almost exclusively in certain age groups.

Edits of the Age, Primary Site, and Morphology require review if a site/morphology combination occurs in an age group for which it is extremely rare. The edit Age, Primary Site, Morph ICDO3--Adult (SEER) edits cases with an Age at Diagnosis of 15 and older. The edit Age, Primary Site, Morph ICDO3--Pediatric (NPCR) edits cases with an Age at Diagnosis of less than 15. The edit Age, Primary Site, Morphology ICDO2 (SEER IF15) contains logic for all ages.

#### Instructions for Coding

1. The data item is to be left blank if the program does not generate an error message (and if the case was not diagnosed in utero) for the edits of the Age, Primary Site, Morphology.
2. Any identified errors should have been corrected for the case if an item is discovered to be incorrect. The data item should be blank for records where identified errors were corrected.

3. Code 1 or 3 indicates that a review of data items in the error or warning message confirmed all were correct.

**Codes**

- 1 Reviewed and confirmed that age/site/histology combination is correct as reported
  - 2 Reviewed and confirmed that case was diagnosed in utero
  - 3 Reviewed and confirmed that conditions 1 and 2 both apply
- Blank Not reviewed or reviewed and corrected.

**Consideration for Use:**

Previous evaluations have shown that over-ride flags may be coded when not needed. These may result when edits are applied by individual state cancer registries that are more stringent than required for the CDC and SEER data submissions. Other instances may result from coding all over-ride flags for an individual record. If a data query results in an age, site, morphology combination that is unexpected, it is recommended that this data item be reviewed in conjunction with those records.

## Section: Over-ride Flags Data Items

### Over-ride SeqNo/DxConf

#### Over-ride Sequence Number/Diagnostic Confirmation Inter-field Review (Inter-field Edit 23)

SAS Alternate Name	Length	Source of Standard
I2000_ORSeqNoDxConf	1	NAACCR Item #2000; SEER

#### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edit in the NAACCR Metafile of the EDITS software:

Inter-field Edit	Description
Diagnostic Confirm, Seq Num--Central (SEER IF23)	Identifies records with multiple primary cancers where at least one primary cancer is not microscopically confirmed

#### Rationale

Some edits check for code combinations that are impossible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See NAACCR Standards for Cancer Registries Volume II: Data Standards and Data Dictionary Chapter IV Recommended Data Edits and Software Coordination of Standards.

#### Over-ride Flag as Used in the EDITS Software Package

- The edit checks if the case is one of multiple primaries and is not microscopically confirmed or has only positive lab test/marker studies (i.e., Diagnostic Confirmation >5) and tumor sequence number >00 (more than one primary).
- The edit is skipped if the Sequence Number--Central is in the range of 60-99.

#### Instructions for Coding

1. The data item is left blank if the program does not generate an error message for the Diagnostic Confirmation and Sequence Number Central edit.
2. Any identified errors should have been corrected for the case if an item is discovered to be incorrect. The data item should be blank for records where identified errors were corrected.
3. Code 1 indicates that a review of data items in the error or warning message verified that there are multiple primary cancers of specific sites in which at least one diagnosis was not microscopically confirmed.

#### Codes

- 1 Reviewed and confirmed as reported
- Blank Not reviewed or reviewed and corrected

#### Consideration for Use:

Previous evaluations have shown that over-ride flags may be coded when not needed. These may result when edits are applied by individual state cancer registries that are more stringent than required for the CDC and SEER data submissions. Other instances may result from coding all over-ride flags for an individual record. If a data query results in a diagnostic confirmation and sequence number-central combination that is unexpected, it is recommended that this data item be reviewed in conjunction with those records.

## Section: Over-ride Flags Data Items Over-ride Site/Lat/Sequence Number

### Over-ride Site/Histology/Laterality/Sequence Number Inter-record Review (Inter-record Edit 09)

SAS Alternate Name	Length	Source of Standard
I2010_ORSiteLatSeqNo	1	NAACCR Item #2010; SEER

#### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

Mature central cancer registries can have up to 15-20% multiple primary data. In order to validate coded values across multiple tumor records for a single patient, inter-record edits must be applied to the data. Inter-record edits compare data recorded across more than one record, and are commonly applied across tumor records for a patient that has multiple tumors. These edits compare codes or groups of codes recorded in the same data item(s) between each of the tumor records for the patient. For example, one inter-record edit compares the sequence numbers of multiple tumors for the same patient with their dates of diagnosis to ensure that the sequence numbers have been assigned in the correct chronological order based on diagnosis date.

This over-ride is used with the following Inter-record Edit from the SEER Program:

Inter-record Edit	Description
Verify Same Primary Not Reported Twice for a Person (SEER IR09)	Identifies records with multiple primary cancers where the date of diagnosis and primary cancer site are within a specified range but the sequence number-central is different

#### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See NAACCR Standards for Cancer Registries Volume II: Data Standards and Data Dictionary Chapter IV Recommended Data Edits and Software Coordination of Standards.

#### Over-ride Flag as Used in the EDITS Software Package

Verify Same Primary Not Reported Twice for a Person (SEER IR09) applies to paired organs and does not allow two cases with the same primary site group, laterality and three digit histology code. This edit verifies that the same primary is not reported twice for a person.

#### Instructions for Coding

1. The data item is left blank if the program does not generate an error message for the edit Verify Same Primary Not Reported Twice for a Person (SEER IR09).
2. Any identified errors should have been corrected if the records are determined to be the same primary cancer. The data item should be blank for records where identified errors were corrected.
3. Code 1 indicates that the case was reviewed and verified that the patient had multiple primaries of the same histology (3 digit) in the same primary site group.



**Codes**

- 1 Reviewed and confirmed as reported
- Blank Not reviewed or reviewed and corrected

**Consideration for Use:**

Previous evaluations have shown that over-ride flags may be coded when not needed. These may result when edits are applied by individual state cancer registries that are more stringent than required for the CDC and SEER data submission. Other instances may result from coding all over-ride flags for an individual record. If a data query results in a primary site, histology, laterality, and sequence number-central combination that is unexpected, it is recommended that this data item be reviewed in conjunction with those records.

## Section: Over-ride Flags Data Items Over-ride Site/Type

### Over-ride Site/Type Inter-field Review (Inter-field Edit 25)

SAS Alternate Name	Length	Source of Standard
I2030_ORSiteType	1	NAACCR Item #2030; SEER

#### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Inter-field Edit	Description
Primary Site, Morphology-Type, Behavior ICDO3 (SEER IF25)	Identifies records where the site/histology/behavior combination is not in the SEER Site/Histology Validation List

#### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case then the over-ride flag is used to skip the edit in the future. See NAACCR Standards for Cancer Registries Volume II: Data Standards and Data Dictionary Chapter IV Recommended Data Edits and Software Coordination of Standards.

#### Over-ride Flag as Used in the EDITS Software Package

This edit checks for “usual” combinations of site and ICD-O-3 histology.

1. The Site/Histology validation list (available on the SEER web site, <http://seer.cancer.gov/icd-o-3/>) contains those histologies commonly found in the specified primary site. Histologies that occur only rarely or never are not included. These edits require review of all combinations not listed.
2. Since basal and squamous cell carcinomas of non-genital skin sites are not reportable to NPCR, these site/histology combinations do not appear on the SEER validation list.

Review of these cases requires investigating whether a) the combination is biologically implausible, or b) there are cancer registry coding conventions that would dictate different codes for the diagnosis. Review of these rare combinations often results in changes to the primary site and/or morphology, rather than a decision that the combination is correct.

#### Instructions for Coding

1. The data item is left blank if the program does not generate an error message for the edit Primary Site, Morphology-Type, Behavior ICDO3 (SEER IF25).
2. Any identified errors should have been corrected if an item is discovered to be incorrect. The data item should be blank for records where identified errors were corrected.
3. Code 1 indicates that the case was reviewed and both the site and histology are correct.

**Codes**

- 1 Reviewed and confirmed as reported
- Blank Not reviewed or reviewed and corrected

**Consideration for Use:**

Previous evaluations have shown that over-ride flags may be coded when not needed. These may result when edits are applied by individual state cancer registries that are more stringent than required for CDC and SEER data submissions. Other instances may result from coding all over-ride flags for an individual record. If a data query results in a primary site, histology, and behavior combination that is unexpected, it is recommended that this data item be reviewed in conjunction with those records.

## Section: Over-ride Flags Data Items

### Over-ride Histology

#### Over-ride Histology/Behavior Inter-field Review

SAS Alternate Name	Length	Source of Standard
I2040_ORHist	1	NAACCR Item #2040; SEER

#### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Inter-field Edit	Description
Diagnostic Confirmation, Behavior ICDO3 (SEER IF31)	Identifies records with a behavior of in situ and a non-microscopic diagnostic confirmation
Morphology--Type/Behavior ICDO3 (SEER MORPH)	

#### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See NAACCR Standards for Cancer Registries Volume II: Data Standards and Data Dictionary Chapter IV Recommended Data Edits and Software Coordination of Standards.

#### Over-ride Flags as Used in the EDITS Software Package

The edit Diagnostic Confirmation, Behavior checks that, for *in situ* cases (Behavior = 2), Diagnostic Confirmation specifies microscopic confirmation (1, 2, or 4).

The distinction between *in situ* and invasive is very important to a registry, since prognosis is so different. Since the determination that a neoplasm has not invaded surrounding tissues, i.e., *in situ*, is made microscopically, cases coded *in situ* in behavior should have a microscopic confirmation code. However, very rarely, a physician will designate a case noninvasive or *in situ* without microscopic evidence.

The edit Morphology--Type/Behavior performs the following check:

1. Codes listed in ICD-O-3 with behavior codes of only 0 or 1 are considered valid, since the behavior matrix allows for the elevation of the behavior of such histologies when the tumor is *in situ* or malignant. This edit forces review of these rare cases to verify that they are indeed *in situ* or malignant.
2. The following ICD-O-3 histologies are generally not accepted as *in situ*: 8000-8005, 8020, 8021, 8331, 8332, 8800-9055, 9062, 9082, 9083, 9110-9493, 9501-9989. This edit forces review of these cases.
3. If a Morphology-Type/Behavior edit produces an error or warning message and the case is one in which the 4-digit morphology code is one that appears in ICD-O-3 only with behavior codes of 0 or 1, or the case is one in which the 4-digit morphology code is not generally accepted with a behavior code of 2, this edit forces review to verify the coding of morphology and that the behavior should be coded malignant or *in situ*.

Exceptions:

If year of Date of Diagnosis > 2000, then a behavior code of 1 is valid for the following ICD-O-3 histologies are valid with a behavior code of 1: 8442, 8451, 8462, 8472, and 8473.

If year of Date of Diagnosis > 2003, the following ICD-O-3 benign histologies will pass without review: 8146, 8271, 8861, 8897, 9121, 9122, 9131, 9161, 9350, 9351, 9352, 9360, 9361, 9383, 9384, 9394, 9412, 9413, 9444, 9492, 9493, 9506, 9531, 9532, 9533, 9534, 9537, 9541, 9550, 9562, and 9570.

4. Grades 5-8 with histologies not in the range of 9590-9948 are impossible.
5. Some terms in ICD-O-3 carry an implied statement of grade. These histologies must be reported with the correct grade as stated below. An error of this type cannot be over-ridden.

### ICD-O-3

8020/34 Carcinoma, undifferentiated

8021/34 Carcinoma, anaplastic

8331/31 Follicular adenocarcinoma, well differentiated

9082/34 Malignant teratoma, undifferentiated

9083/32 Malignant teratoma, intermediate type

9401/34 Astrocytoma, anaplastic

9451/34 Oligodendroglioma, anaplastic

9511/31 Retinoblastoma, differentiated

9512/34 Retinoblastoma, undifferentiated

### Instructions for Coding

1. The data item is left blank if the program does not generate an error message for the edit Diagnostic Confirmation, Behavior ICDO3 (SEER IF31) or Morphology--Type/Behavior ICDO3 (SEER MORPH).
2. Any identified errors should have been corrected if an item is discovered to be incorrect. The data item should be blank for records where identified errors were corrected.
3. Code 1, 2, or 3 indicates that the case was reviewed and confirms that the data are correct.

### Codes

- 1 Reviewed and confirmed that the pathologist states the primary to be “*in situ*” or “malignant” although the behavior code of the histology is designated as “benign” or “uncertain” in ICD-O-2 or ICD-O-3
  - 2 Reviewed and confirmed that the behavior code is “*in situ*,” but the case is not microscopically confirmed
  - 3 Reviewed and confirmed that conditions 1 and 2 both apply
- Blank Not reviewed or reviewed and corrected

### Consideration for Use:

Previous evaluations have shown that over-ride flags may be coded when not needed. These may result when edits are applied by individual state cancer registries that are more stringent than required for the CDC and SEER data submissions. Other instances may result from coding all over-ride flags for an individual record. If a data query results in a diagnostic confirmation, histology, and behavior combination that is unexpected, it is recommended that this data item be reviewed in conjunction with those records.

## Section: Over-ride Flags Data Items Over-ride Report Source

### Over-ride Type of Reporting Source/Sequence Number Inter-field Review (Inter-field Edit 04)

SAS Alternate Name	Length	Source of Standard
I2050_ORRptSrc	1	NAACCR Item #2050; SEER

#### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Inter-field Edit	Description
Type of Rep Srce(DC),Seq Num--Cent, ICDO3 (SEER IF04)	Identifies records with multiple primary cancers where one is reported only through a death certificate and histology code is <9590

#### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See NAACCR Standards for Cancer Registries Volume II: Data Standards and Data Dictionary Chapter IV Recommended Data Edits and Software Coordination of Standards.

#### Over-ride Flag as Used in the EDITS Software Package

The edit Type of Rep Srce(DC), Seq Num—Cent checks that if the case is a death-certificate-only case and the histology is not a lymphoma, leukemia, immunoproliferative, or myeloproliferative disease (ICD-O-3 histology is less than 9590), then the tumor sequence number must specify one primary only (sequence '00').

#### Instructions for Coding

1. The data item is left blank if the program does not generate an error message for the reporting source edit.
2. Any identified errors should have been corrected if an item is discovered to be incorrect. The data item should be blank for records where identified errors were corrected.
3. Code 1 indicates that the case was reviewed, confirms that the type of reporting source, histologic type, and tumor sequence number data are correct, verifies that a second or subsequent primary with a reporting source of death-certificate-only has been reviewed and is indeed an independent primary.

#### Codes

- 1           Reviewed and confirmed as reported  
Blank   Not reviewed or reviewed and corrected

#### Consideration for Use:

Previous evaluations have shown that over-ride flags may be coded when not needed. These may result when edits are applied by individual state cancer registries that are more stringent than required for the CDC and SEER data submissions. Other instances may result from coding all over-ride flags for an individual record. If a data query results in a type of reporting source, histologic type, and tumor sequence number combination that is unexpected, it is recommended that this data item be reviewed in conjunction with those records.

## Section: Over-ride Flags Data Items

### Over-ride Ill-define Site

#### Over-ride Sequence Number/Ill-defined Site Inter-field Review (Inter-field Edit 22)

SAS Alternate Name	Length	Source of Standard
I2060_ORIlldefineSite	1	NAACCR Item #2060; SEER

#### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Inter-field Edit	Description
Seq Num--Central, Prim Site, Morph ICDO3 (SEER IF22)	Identifies records with multiple primary cancers where one is reported as an ill-defined primary site

#### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See NAACCR Standards for Cancer Registries Volume II: Data Standards and Data Dictionary Chapter IV Recommended Data Edits and Software Coordination of Standards.

#### Over-ride Flag as Used in the EDITS Software Package

The edit forces review of multiple primary cancers when one of the primaries is coded to a site/morphology combination that could indicate a metastatic site rather than a primary site.

1. If Sequence Number-Central indicates the person has had more than one primary, then any case with one of the following site/histology combinations requires review:
  - C760-C768 (ill-defined sites) or C809 (unknown primary) and ICD-O-3 histology < 9590.
  - C770-C779 (lymph nodes) and ICD-O-3 histology not in the range 9590-9729; or C420-C424 and ICD-O-3 histology not in the range 9590-9989. That combination is most likely a metastatic lesion.
  - Any site ICD-O-3 histology in the range 9740-9758.
2. If it turns out that the suspect tumor is a manifestation of one of the patient's other cancers, the metastatic or secondary case is deleted, remaining cases are re-sequenced, and the coding on the original case is corrected as necessary.

#### Instructions for Coding

1. The data item is left blank if the program does not generate an error message for the ill-defined primary site edit.
2. Any identified errors should have been corrected if an item is discovered to be incorrect. The data item should be blank for records where identified errors were corrected.
3. Code 1 indicates that the case was reviewed and confirms that a second or subsequent primary report with an ill-defined primary site is indeed an independent primary.

#### Codes



- 1 Reviewed and confirmed as reported: a second or subsequent primary reported with an ill-defined primary site (C76.0-C76.8, C80.9) has been reviewed and is an independent primary
- Blank Not reviewed or reviewed and corrected

**Consideration for Use:**

Previous evaluations have shown that over-ride flags may be coded when not needed. These may result when edits are applied by individual state cancer registries that are more stringent than required for the CDC and SEER data submissions. Other instances may result from coding all over-ride flags for an individual record. If a data query results in a primary site, histologic type, and tumor sequence number combination that is unexpected, it is recommended that this data item be reviewed in conjunction with those records.

## Section: Over-ride Flags Data Items

### Over-ride Leuk, Lymphoma

#### Over-ride Leukemia or Lymphoma/Diagnostic Confirmation Inter-field Review (Inter-field Edit 48)

SAS Alternate Name	Length	Source of Standard
I2070_ORLeukLymph	1	NAACCR Item #2070; SEER

#### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Inter-field Edit	Description
Diagnostic Confirmation, Histology ICDO3 (SEER IF48)	Identifies leukemia and lymphoma records where the diagnostic confirmation is not microscopic

#### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See NAACCR Standards for Cancer Registries Volume II: Data Standards and Data Dictionary Chapter IV Recommended Data Edits and Software Coordination of Standards.

#### Over-ride Flag as Used in the EDITS Software Package

Since lymphoma and leukemia are almost exclusively microscopic diagnoses, this edit forces review of any cases of lymphoma records that have a diagnostic confirmation of direct visualization or clinical, and any leukemia with a diagnostic confirmation of direct visualization.

#### Instructions for Coding

1. The data item is left blank if the program does not generate an error message for the Diagnostic Confirmation, Histology edit.
2. Any identified errors should have been corrected if an item is discovered to be incorrect. The data item should be blank for records where identified errors were corrected.
3. Code 1 indicates that the case was reviewed and confirms that the histologic type and diagnostic confirmation are correctly coded. Positive hematologic findings and bone marrow specimens are included as histologic confirmation (code 1 in Diagnostic Confirmation) for leukemia.

#### Codes

- 1           Reviewed and confirmed as reported  
 Blank   Not reviewed or reviewed and corrected

#### Consideration for Use:

Previous evaluations have shown that over-ride flags may be coded when not needed. These may result when edits are applied by individual state cancer registries that are more stringent than required for the CDC and SEER data submissions. Other instances may result from coding all over-ride flags for an

individual record. If a data query results in a diagnostic confirmation and histologic type combination that is unexpected, it is recommended that this data item be reviewed in conjunction with those records.

## Section: Over-ride Flags Data Items

### Over-ride Site/Behavior

#### Over-ride Flag for Site/Behavior (IF39)

SAS Alternate Name	Length	Source of Standard
I2071_ORSiteBehav	1	NAACCR Item #2071; SEER

#### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Inter-field Edit	Description
Primary Site, Behavior Code ICDO3 (SEER IF39)	Identifies records with a non-specific primary cancer site code with an <i>in situ</i> behavior

#### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See NAACCR Standards for Cancer Registries Volume II: Data Standards and Data Dictionary Chapter IV Recommended Data Edits and Software Coordination of Standards.

#### Over-ride Flag as Used in the EDITS Software Package

The edit, Primary Site, Behavior Code, requires review of the following primary sites with a behavior of *in situ* (ICD-O-2 or ICD-O-3 behavior = 2):

- C269 Gastrointestinal tract, NOS
- C399 Ill-defined sites within respiratory system
- C559 Uterus, NOS
- C579 Female genital tract, NOS
- C639 Male genital organs, NOS
- C689 Urinary system, NOS
- C729 Nervous system, NOS
- C759 Endocrine gland, NOS
- C760-C768 Ill-defined sites
- C809 Unknown primary site

Since the designation of *in situ* is very specific and almost always requires microscopic confirmation, ordinarily specific information should also be available regarding the primary site. Conversely, if inadequate information is available to determine a specific primary site, it is unlikely that information about a cancer being *in situ* is reliable.

If an *in situ* diagnosis is stated, more specific primary site information should be sought. A primary site within an organ system can sometimes be identified based on the diagnostic procedure or treatment given or on the histologic type. When no more specific site can be determined, a behavior code of 3 is usually

assigned. In the exceedingly rare situation in which it is certain that the behavior is *in situ* and no more specific site code is applicable, Over-ride Site/Behavior is set to 1.

### **Instructions for Coding**

1. The data item is left blank if the program does not generate an error message for the Primary Site, Behavior Code ICDO3 (SEER IF39) edit.
2. Any identified errors should have been corrected if an item is discovered to be incorrect. The data item should be blank for records where identified errors were corrected.
3. Code 1 indicates that the case was reviewed and confirms that the *in situ* behavior and nonspecific site are correctly coded and that no further information about the primary site is available.

### **Codes**

- |       |  |
|-------|--|
| 1     | Reviewed and confirmed as reported     |
| Blank | Not reviewed or reviewed and corrected |

### **Consideration for Use:**

Previous evaluations have shown that over-ride flags may be coded when not needed. These may result when edits are applied by individual state cancer registries that are more stringent than required for the CDC and SEER data submissions. Other instances may result from coding all over-ride flags for an individual record. If a data query results in a primary site and behavior combination that is unexpected, it is recommended that this data item be reviewed in conjunction with those records.

## Section: Over-ride Flags Data Items

### Over-ride Site/Lat/Morph

#### Over-ride for Site/Laterality/Morphology (IF42)

SAS Alternate Name	Length	Source of Standard
I2074_ORSiteLatMorph	1	NAACCR Item #2074; SEER

#### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Inter-field Edit	Description
Laterality, Primary Site, Morph ICDO3 (SEER IF42)	Identifies records with a paired organ as the primary cancer site code with an <i>in situ</i> behavior and laterality is not coded to 1, 2, or 3.

#### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

#### Over-ride Flag as Used in the EDITS Software Package

The edit Laterality, Primary Site, Morph requires that if the Primary Site is a paired organ and ICD-O-3 behavior is *in situ* (2), then laterality must be 1, 2, or 3.

The intent of this edit is to force review of *in situ* cases for which laterality is coded 4 (bilateral) or 9 (unknown laterality) as to origin. In rare instances when the tumor is truly midline (9) or the rare combination is otherwise confirmed correct, code 1 is entered for Override Site/Lat/Morph.

#### Instructions for Coding

1. The data item is left blank if the program does not generate an error message for the ity, Primary site, Morph ICDO3 (SEER IF42) edit.
2. Any identified errors should have been corrected if an item is discovered to be incorrect. The data item should be blank for records where identified errors were corrected.
3. Code 1 indicates that the case was reviewed and confirms that the *in situ* behavior and laterality are correctly coded.

#### Codes

- 1            Reviewed and confirmed as reported  
 Blank      Not reviewed or reviewed and corrected

#### Consideration for Use:

Previous evaluations have shown that over-ride flags may be coded when not needed. These may result when edits are applied by individual state cancer registries that are more stringent than required for the CDC and SEER data submissions. Other instances may result from coding all over-ride flags for an

individual record. If a data query results in a primary site and behavior combination that is unexpected, it is recommended that this data item be reviewed in conjunction with those records.

**Section: Appendix I**  
**NPCR\_9811\_AnalyticFile\_CS vars\_shell program.sas**  
**(Only for example)**

```
libname in "";

data one;
set in.npcrfull2013_aid ;

css_flag=0;

*** Exclude non-reportable cases ***;
if npcrrptl=1;
if subm_st in ('PR','PI') then css_flag=9;

*** Exclude Invalid Age & unknown/other Sex ***;
if I230_AgeDx='999' then css_flag=2;
if I220_Sex='9' | I220_Sex='3' | I220_Sex='4' | I220_Sex='5' then css_flag=3;

***ELIMINATE SINGLE FIELD EDIT ERRORS;
if E_CSF_AgeDx=1 | E_CSF_Site=1 | E_CSF_Race1=1 | E_CSF_Sex=1 then css_flag=4;

*** delete interfield edit errors ***;
if E_CIF_NAACCRIF13=1 | E_CIF_SEERIF15=1 | E_CIF_NAACCRIF47=1 | E_CIF_SEERIF17=1
then css_flag=5;

*** ICD-O-3 flags (new in 2004 submission mj);
if E_CIF_SEERMorph ge 1 | E_CIF_SEERIF39=1 | E_CIF_SEERIF38=1 | E_CIF_SEERIF15=1 then
css_flag = 11;

*** delete records prior to reference year or 12-23 month old data ***;
if subm_st='AZ' | subm_st='CA' | subm_st='CO' | subm_st='GA' | subm_st='ID' |
  subm_st='IN' | subm_st='KY' | subm_st='MT' | subm_st='NH' | subm_st='NJ' |
  subm_st='NE' | subm_st='NV' | subm_st='PA' | subm_st='RI' | subm_st='WV' |
  subm_st='WA' then refyear='1995';
else if subm_st='AL' | subm_st='AK' | subm_st='DC' | subm_st='MS' | subm_st='MO' |
  subm_st='NY' | subm_st='OH' | subm_st='OR' | subm_st='SC' | subm_st='WY' then
  refyear='1996';
else if subm_st='AR' | subm_st='DE' | subm_st='ND' | subm_st='OK' then refyear='1997';
if dxyear<refyear then css_flag=7;

***remove PR and PI;
if subm_st='PR' | subm_st='PI' then delete;

if I380_SeqNoCntrl in ('0 ','1 ') or I440_Grade = '0' then
  put "left in analysis, but invalid seqno or grade "
  I523_BehavICDO3= I522_HistTypeICDO3= I440_Grade= subm_st= dxyear= I380_SeqNoCntrl=;

hist2_s=substr(I420_Hist_9200_ICDO2,1,2);
```



```

hist3_s=substr(I522_HistTypeICDO3,1,2);

*** Re-define vital status to match SEER ***;
if I1760_VitalStatus='0' then I1760_VitalStatus='4';

sitenum=substr(I400_Site,2,3)+0;

*** combine insite and invasives for urinary bladder;
*** add codes for ICD-O-3 fields mj;
*** fix before create behanal variable;

if ('C670' <= I400_Site <= 'C679')and (I522_HistTypeICDO3 < '9590' or I522_HistTypeICDO3 > '9989')
then do;
    I523_BehavICDO3 = 3;
    behanal = '3';
    if dxyear<2004 then I760_SS1977=1;
        if dxyear<2004 then I759_SS2000=1;
            urin3flag= 1;
    end;

** recode astrocytomas to malignant **;
else if I522_HistTypeICDO3 in ('9421','9422') then behanal = '3';
else if I523_BehavICDO3=3 & ((8000<=I522_HistTypeICDO3<=8930 |
8932<=I522_HistTypeICDO3<=9132 | 9134<=I522_HistTypeICDO3<=9392 |
9394<=I522_HistTypeICDO3<=9537 |
9539<=I522_HistTypeICDO3<=9949 | 9951<=I522_HistTypeICDO3<=9959 |
9963<=I522_HistTypeICDO3<=9979 | I522_HistTypeICDO3=9988) |
(I522_HistTypeICDO3=9133 & (.<sitenum<340 | sitenum>349))) then behanal='3';
** set to 4 any borderline to malignant histology - see Appendix 6 in ICD-O-3 **;
else if I523_BehavICDO3=3 & (I522_HistTypeICDO3 in
(8931,9393,9538,9950,9960,9961,9962,9980,9982,9983,9984,9985,9986,9987,9989) |
(I522_HistTypeICDO3=9133 & 340<=sitenum<=349)) then behanal='4';
** set to 5 any malignant to borderline histology - see Appendix 6 in ICD-O-3 **;
else if I523_BehavICDO3=1 & I522_HistTypeICDO3 in (8442,8451,8462,8472,8473) then behanal='5';
else if I523_BehavICDO3=2 then behanal = '2';
else behanal='9';

brthyear=input(substr(I240_DOB,5,4),$char4.);
brthmnth=input(substr(I240_DOB,1,2),$char2.);
fuyear=input(substr(I1750_DateLastContact,5,4),$char4.);
fumnth=input(substr(I1750_DateLastContact,1,2),$char2.);
primsite=input(substr(I400_Site,2,3),$char3.);
dxmnth=input(substr(I390_DateDx,1,2),$char2.);
dxday=input(substr(I390_DateDx,3,2),$char2.);
dxmoday=input(substr(I390_DateDx,1,4),$char4.);
statenum=stfips(subm_st);

if statenum<10 then state=input('0'||trim(left(statenum)),$char2.);
else if statenum>=10 then state=input(trim(left(statenum)),$char2.);

if subm_st in ('KS','MN') then I90_CountyDx='000';

```

```

***fix CO counties;
if subm_st='CO' and dxyear<=2001 then do;
    if I90_CountyDx='001' then I90_CountyDx='911';
    else if I90_CountyDx='013' then I90_CountyDx='912';
    else if I90_CountyDx='059' then I90_CountyDx='913';
    else if I90_CountyDx='123' then I90_CountyDx='914';
    end;

stcty=input(stfips||I90_CountyDx, $char5.);
state99=stfips;

*** define race recode (w, b, ai/an, api) ***;
if I160_Race1 = '01' then racerec='1';    *** white;
else if I160_Race1 = '02' then racerec='2';    *** black;
else if I160_Race1 in ('03') then racerec = '3';    *** AI/AN;
else if I160_Race1 in ('98') then racerec = '5';    *** other unspecified;
else if I160_Race1 = '99' then racerec = '9';    *** unknown;
else if I160_Race1 in
('04','05','06','07','08','09','10','11','12','13','14','15','16','17','20','21','22','25','26','27','28',
'30','31','32','96','97') then racerec = '4';    *** API;
else racerec=' ';

*** if white, check race2 ***;
if racerec='1' then do;
    if I161_Race2 = '02' then racerec='2';    *** black;
    else if I161_Race2 in ('03') then racerec = '3';    *** AI/AN;
    else if I161_Race2 in
('04','05','06','07','08','09','10','11','12','13','14','15','16','17','20','21','22','25','26','27','28',
'30','31','32','96','97') then racerec = '4';    *** API;
end;

*** if white, check ihslink ***;
if subm_st in ('AL','AZ','AR','CA','CO','DE','DC','FL','GA','ID','IL','IN','KS',
'KY','LA','ME','MD','MA','MI','MN','MS','MO','MT','NE','NV','NH','NJ',
'NY','NC','ND','OH','OK','OR','PA','RI','SC','SD','TN','TX','VT','VA',
'WA','WV','WI','WY') then do;
    if racerec in ('1','5','9') & I192_IHS='1' then racerec='3';
end;

if I191_NHIA=0 then nhiaoth='0';
else if 1<=I191_NHIA<=8 then nhiaoth='1';

*** Create certification variable ***;
*** PW is Palau;
uscsstd = '1';
if dxyear = '2002' and subm_st in ('DC','MS','TN') then uscsstd = '0';
else if dxyear = '2001' and subm_st in ('MS','TN','VA') then uscsstd = '0';
else if dxyear = '2000' and subm_st in ('AR','MS','NC','SD','TN','VA') then uscsstd = '0';
else if dxyear = '1999' and subm_st in ('AR','MS','NC','SD','TN','VA') then uscsstd = '0';
else if dxyear = '1998' and subm_st in ('AR','GA','MD','MS','NC','NH','SD','TN','VA') then uscsstd = '0';

```

```
uscs9808 = '1';
if subm_st in ('AR','DC','GA','MD','MS','NC','NH','SD','TN','VA') then uscs9808 = '0';

uscs9908 = '1';
if subm_st in ('AR','DC','MS','NC','SD','TN','VA') then uscs9908 = '0';

uscs0408 = '1';

program='01';
retain cnt 0;
cnt+1;

if 1995<=fuyear<=2009 then nfuyear=fuyear;
else nfuyear=9999;

run;
```